
<system_role>You are a strict, meticulous, and objective research article evaluation expert. You excel at using specific assessment criteria to deeply compare two articles on the same task, providing precise scores and clear justifications.</system_role>

<user_prompt>
**Task Background**
There is a deep research task, and you need to evaluate two research articles written for this task. We will assess the articles across four dimensions: Comprehensiveness, Insight, Instruction Following, and Readability. The content is as follows:
<task>
"Could the rapeutic interventions aimed at modulating plasma metal ion concentrations represent effective preventive or therapeutic strategies against cardiovascular diseases? What types of interventions—such as supplementation—have been proposed, and is there clinical evidence supporting their feasibility and efficacy?"
</task>

**Articles to Evaluate**
<article_1>
"# **Modulating Plasma Metal Ion Concentrations: A Critical Evaluation of Preventive and Therapeutic Strategies for Cardiovascular Diseases**

## **1\. Introduction**

### **1.1. Metal Ion Homeostasis and Cardiovascular Disease: An Overview**

Metal ions, encompassing both essential bulk elements and trace minerals, are indispensable for life, participating fundamentally in nearly all basic biological processes within the human body. Their roles extend from serving as crucial cofactors for a vast number of enzymes, enabling catalytic activity essential for metabolic reactions, to maintaining the structural integrity and function of cellular components. Indeed, studies suggest over half of modern metabolic pathways rely on metal ions. However, the physiological concentrations of these ions must be maintained within narrow limits, as disruptions in metal ion equilibrium are frequently implicated in the pathogenesis of numerous diseases, including cardiovascular diseases (CVDs). Such imbalances are associated with a variety of disturbances in physiological processes that culminate in abnormal cardiac structure and function.

It is critical to differentiate between essential metal ions, which possess defined biological roles, and non-essential metals, often termed heavy metals. Essential ions pertinent to cardiovascular health include magnesium (Mg), calcium (Ca), potassium (K), zinc (Zn), copper (Cu), selenium (Se), iron (Fe), and manganese (Mn). These elements participate in processes ranging from oxygen transport and energy metabolism to antioxidant defense and signal transduction. Conversely, non-essential heavy metals such as lead (Pb), cadmium (Cd), arsenic (As), mercury (Hg), and chromium (Cr) lack known beneficial biological functions and can exert toxic effects even at very low concentrations. Chronic environmental or occupational exposure to these heavy metals represents an increasingly recognized, though often underestimated, risk factor for the development and progression of CVDs, including hypertension, atherosclerosis, and arrhythmias. It is also important to recognize that even essential trace elements can become toxic if their intake or accumulation exceeds physiological requirements, underscoring the concept of a double-edged sword where both deficiency and excess can be detrimental.

### **1.2. Rationale for Modulating Metal Ions as a Therapeutic Strategy**

Given the established links between metal ion dyshomeostasis and CVD pathophysiology, the modulation of plasma and tissue concentrations of specific ions has emerged as a potential therapeutic or preventive strategy. The central premise is that correcting existing imbalances—addressing either deficiency or overload—could mitigate cardiovascular risk or ameliorate established disease. Compared to some conventional pharmacological agents, metal ions offer potential advantages such as broad availability, inherent stability, relatively low cost, and potentially favorable safety profiles when used appropriately.

Several distinct intervention strategies have been proposed and investigated:

*   **Supplementation:** Providing exogenous metal ions, typically orally or intravenously, to correct deficiencies or achieve pharmacological concentrations. This is relevant for essential minerals like magnesium, zinc, selenium, and iron.
*   **Chelation Therapy:** Administering agents that bind specific metal ions, facilitating their removal from the body. This is primarily used to treat metal overload or toxicity, such as iron overload in thalassemia, copper overload in Wilson's disease, or potentially to reduce the body burden of toxic heavy metals like lead and cadmium. EDTA chelation has also been controversially proposed for atherosclerosis, partly based on the hypothesis of removing calcium from plaques.
*   **Dietary Modification:** Adjusting dietary patterns to increase or decrease the intake of specific minerals through food sources.

### **1.3. Aim and Structure of the Report**

This report aims to provide a comprehensive and critical evaluation of the current scientific and clinical evidence concerning the feasibility, efficacy, and safety of therapeutic interventions designed to modulate plasma metal ion concentrations for the prevention or treatment of cardiovascular diseases. It will synthesize information from preclinical studies, observational epidemiology, randomized controlled trials (RCTs), and systematic reviews/meta-analyses. The report will first detail the roles of key metal ions in cardiovascular physiology and pathophysiology. Subsequently, it will examine the clinical evidence for specific interventions targeting magnesium, zinc, selenium, copper, and iron. The use of chelation therapy, particularly EDTA for atherosclerosis and iron/copper chelation for overload states, will be critically assessed. Underlying biological mechanisms, safety considerations, diagnostic challenges, and future research directions will be discussed. Finally, a synthesis will evaluate the overall potential and limitations of modulating metal ions as a cardiovascular therapeutic strategy, highlighting the strength of evidence for specific approaches.

## **2\. Roles of Key Metal Ions in Cardiovascular Physiology and Pathophysiology**

### **2.1. Essential Functions and Homeostatic Mechanisms**

A delicate balance of essential metal ions is fundamental for normal cardiovascular function. Each ion performs specific roles, often acting as cofactors for enzymes or participating directly in signaling and structural processes.

*   **Magnesium (Mg):** A crucial intracellular cation, Mg$^{2+}$ is vital for mitochondrial function and cellular respiration. It plays a significant role in regulating various cation channels, including potassium (K+) and calcium (Ca2+) channels, thereby influencing the electrical properties and excitability of myocardial and vascular smooth muscle cells. By modulating intracellular calcium influx, Mg$^{2+}$ also affects myocardial contractility and vascular tone.
*   **Calcium (Ca):** Intracellular Ca2+ dynamics are central to cardiac excitation-contraction coupling, linking electrical stimulation to mechanical contraction. Calcium also plays critical roles in mitochondrial metabolism and serves as a ubiquitous second messenger in various signaling pathways relevant to cardiac function and remodeling.
*   **Potassium (K):** As the primary intracellular cation, K+ gradients across the cell membrane are the main determinant of the resting membrane potential in cardiomyocytes. K+ channels are essential for cardiac repolarization and maintaining normal cardiac rhythm.
*   **Zinc (Zn):** Although not directly redox-active, Zn$^{2+}$ is an essential cofactor for numerous enzymes, including superoxide dismutase (SOD1/3) and metallothioneins, which are involved in antioxidant defense. It also plays structural roles in proteins, participates in immune function, is crucial for insulin metabolism and signaling, and modulates the activity of multiple ion channels, including Ca2+, K+, and transient receptor potential (TRP) channels in vascular smooth muscle, potentially contributing to vasorelaxation.
*   **Copper (Cu):** Copper is a critical cofactor for enzymes involved in vital cardiovascular processes, such as SOD1 (antioxidant defense) and cytochrome c oxidase (CcO) in the mitochondrial electron transport chain for energy production. It is also involved in angiogenesis, connective tissue crosslinking (lysyl oxidase), and iron mobilization (ceruloplasmin).
*   **Selenium (Se):** Selenium exerts its biological functions primarily through incorporation into selenoproteins, such as glutathione peroxidases (GPx), which are critical antioxidant enzymes protecting against oxidative damage. It also plays roles in thyroid hormone metabolism and immune function.
*   **Iron (Fe):** Iron is indispensable for oxygen transport via hemoglobin in red blood cells and oxygen storage via myoglobin in muscle tissue. It is a key component of heme proteins and iron-sulfur clusters in the mitochondrial electron transport chain, essential for ATP production. Iron also serves as a cofactor for various enzymes.
*   **Manganese (Mn):** Manganese functions as a cofactor for several enzymes, including mitochondrial SOD2 (MnSOD), playing a role in antioxidant defense. It can activate the Keap1-Nrf2 antioxidant pathway and is involved in glycosylation processes within the Golgi apparatus.

The homeostasis of these ions is tightly regulated through complex processes involving intestinal absorption, transport via specific proteins (e.g., albumin, transferrin, ceruloplasmin), cellular uptake and efflux transporters (e.g., ZIP and ZnT transporters for zinc), tissue storage (e.g., iron in ferritin), and excretion (primarily renal and fecal routes). Disease states, inflammation, genetic factors, medications, and nutritional status can disrupt these homeostatic mechanisms, leading to deficiency or overload. Notably, the status of one metal ion can influence the metabolism of another; for instance, copper is essential for iron mobilization via ceruloplasmin activity, and high zinc intake can impair copper absorption. This interconnectedness necessitates a holistic perspective when considering the impact of modulating any single ion.

### **2.2. Links Between Dyshomeostasis and CVD Pathogenesis**

Disturbances in the homeostasis of essential and trace minerals, as well as exposure to toxic heavy metals, are implicated in the pathogenesis and progression of various CVDs through multiple overlapping mechanisms.

*   **Oxidative Stress:** This is a central mechanism linking metal ion imbalance to CVD. Deficiency of antioxidant minerals like Mg, Zn, Se, and Cu can impair the function of key protective enzymes (SOD, GPx, Catalase), leading to increased reactive oxygen species (ROS). Conversely, excess redox-active metals like iron and copper can catalyze the formation of highly damaging hydroxyl radicals via Fenton and Haber-Weiss reactions. Toxic heavy metals (Pb, Cd, As, Hg) can also induce oxidative stress by depleting endogenous antioxidants (like glutathione) or directly generating ROS. This oxidative damage affects lipids, proteins, and DNA, contributing to endothelial dysfunction, inflammation, and cell death.
*   **Inflammation:** Metal ion status is closely linked to inflammatory processes. Low magnesium levels are associated with elevated systemic inflammation markers like high-sensitivity C-reactive protein (hs-CRP). Zinc deficiency can promote the release of pro-inflammatory cytokines (e.g., IL-6, TNF-α). Heavy metals can also trigger inflammatory responses. Chronic inflammation is a key driver of atherosclerosis and adverse cardiac remodeling.
*   **Endothelial Dysfunction:** The endothelium plays a critical role in regulating vascular tone, inflammation, and thrombosis, primarily through the production of nitric oxide (NO). Oxidative stress and inflammation induced by metal ion imbalances can impair endothelial function by reducing NO bioavailability (e.g., through ROS-mediated degradation of NO or reduced eNOS activity). Direct toxic effects of heavy metals or copper dysregulation can also damage endothelial cells.
*   **Ion Channel Dysregulation:** Ions like Mg$^{2+}$ and Zn$^{2+}$ directly influence the function of cardiac and vascular ion channels (K+, Ca2+, TRP channels), affecting cardiac electrophysiology (action potential duration, conduction) and vascular tone. Deficiencies (e.g., hypomagnesemia) or excesses can therefore contribute to arrhythmias and hypertension. Calcium dyshomeostasis is fundamental to arrhythmias, contractile dysfunction, and mitochondrial damage in cardiac fibrosis.
*   **Cardiac Remodeling and Fibrosis:** Pathological remodeling involving hypertrophy and fibrosis underlies many forms of heart failure. Imbalances in iron (both deficiency and overload), copper, calcium, and zinc metabolism have been implicated in promoting cardiac fibrosis. Mechanisms involve redox dysregulation, mitochondrial dysfunction, activation of fibroblasts, and altered extracellular matrix turnover.
*   **Atherosclerosis:** This multifactorial process is driven by endothelial dysfunction, inflammation, lipid deposition, and oxidative stress, all of which can be influenced by metal ion status. Dysregulation of Zn, Cu, and Fe, as well as exposure to heavy metals like Pb, Cd, and As, have been linked to the promotion of atherosclerosis.
*   **Arrhythmias:** Clinical and experimental evidence links magnesium deficiency to an increased risk of various arrhythmias, including atrial fibrillation (AF) and potentially lethal ventricular arrhythmias like Torsades de Pointes. Copper dysregulation and heavy metal toxicity may also contribute to arrhythmogenesis. Zinc administration has been suggested to improve arrhythmias.
*   **Heart Failure (HF):** Deficiencies of magnesium and iron are highly prevalent and prognostically important comorbidities in HF. Copper deficiency can lead to cardiomyopathy, while iron and copper overload are known causes of toxic cardiomyopathy.
*   **Metal-Induced Cell Death:** Beyond general toxicity, specific regulated cell death pathways driven by metal ions are increasingly recognized in CVD. Ferroptosis (iron-dependent lipid peroxidation), cuproptosis (copper-dependent cell death linked to mitochondrial protein aggregation), and other pathways like apoptosis and necroptosis influenced by metal ions contribute to myocardial injury in conditions like diabetic cardiomyopathy and ischemia-reperfusion injury.

The impact of many essential trace elements often follows a U-shaped or J-shaped curve, where both deficiency and excess relative to physiological needs confer increased cardiovascular risk. This context-dependency highlights that therapeutic strategies must aim for restoring balance rather than simply increasing or decreasing levels. Furthermore, accurately defining deficiency or excess can be challenging, particularly for ions like iron, where commonly used serum markers like ferritin can be influenced by inflammation (an acute phase reactant), potentially misrepresenting true tissue iron stores, especially in chronic inflammatory conditions like heart failure. This diagnostic uncertainty complicates the identification of patients who would truly benefit from intervention.

The convergence of multiple different ion imbalances onto common downstream pathways—namely oxidative stress, inflammation, and endothelial dysfunction—suggests that these processes are central nodes mediating metal-related cardiovascular damage. This convergence offers potential therapeutic targets that might address the consequences of various ion disturbances simultaneously.

**Table 1: Overview of Key Metal Ions, Cardiovascular Roles, and Pathophysiological Links**

| Metal Ion        | Key Physiological Roles in CV System                                                                  | Consequences of Deficiency in CVD                                                                        | Consequences of Excess/Overload in CVD                                                              | Key Pathomechanisms Involved                                                                         | Relevant Sources |
| :--------------- | :---------------------------------------------------------------------------------------------------- | :------------------------------------------------------------------------------------------------------- | :-------------------------------------------------------------------------------------------------- | :--------------------------------------------------------------------------------------------------- | :--------------- |
| **Magnesium (Mg)** | Mitochondrial function, ATP metabolism, ion channel (K+, Ca2+) regulation, vasodilation, enzyme cofactor | Hypertension, arrhythmias (AF, TdP), coronary artery calcification, HF risk (esp. in diabetes), endothelial dysfunction, ↑inflammation/oxidative stress | Generally well-tolerated orally; hypermagnesemia (rare, usually renal failure) causes hypotension, bradycardia, conduction block | Oxidative stress, inflammation, endothelial dysfunction, ion channel modulation, mitochondrial dysfunction |                  |
| **Calcium (Ca)**   | Excitation-contraction coupling, signaling, mitochondrial metabolism                                  | (Severe deficiency rare, affects contractility)                                                          | Vascular calcification (complex role), mitochondrial Ca2+ overload → ROS, cell death, fibrosis         | Mitochondrial dysfunction, oxidative stress, apoptosis, fibrosis, excitation-contraction coupling    |                  |
| **Potassium (K)**  | Membrane potential, cardiac repolarization, vascular tone                                             | Arrhythmias (hypokalemia), muscle weakness                                                               | Arrhythmias (hyperkalemia), conduction block                                                        | Electrophysiology, membrane potential                                                                | (General Physiology) |
| **Zinc (Zn)**      | Antioxidant enzyme cofactor (SOD), anti-inflammatory, insulin signaling, ion channel modulation, vascular health | ↑Oxidative stress/inflammation, endothelial dysfunction, apoptosis, impaired metabolism, ↑CVD risk (esp. in T2D), potential link to CAD | Copper deficiency (high doses), potential GI upset                                                  | Oxidative stress, inflammation, endothelial dysfunction, apoptosis, ion channel modulation, insulin resistance |                  |
| **Copper (Cu)**    | Mitochondrial respiration (CcO), antioxidant (SOD1), angiogenesis, connective tissue, iron metabolism   | Cardiac hypertrophy, HF, impaired mitochondrial function, potentially IHD                                  | Oxidative stress, mitochondrial damage, endothelial dysfunction, atherosclerosis, arrhythmias, cardiomyopathy, cuproptosis | Oxidative stress, mitochondrial dysfunction, angiogenesis, fibrosis, cuproptosis, inflammation       |                  |
| **Selenium (Se)**  | Antioxidant (GPx, selenoproteins), immune function, thyroid metabolism                                | Cardiomyopathy (Keshan disease), increased oxidative stress                                              | Potential ↑T2D risk, toxicity (selenosis) at high levels, alopecia, dermatitis                      | Oxidative stress, inflammation, mitochondrial function                                               |                  |
| **Iron (Fe)**      | O2 transport/storage (Hb/Mb), mitochondrial respiration, enzyme cofactor                                | Anemia, impaired exercise capacity, ↑HF severity/mortality, mitochondrial dysfunction, fibrosis (in HF context) | Cardiomyopathy, HF, arrhythmias, fibrosis, ↑oxidative stress, ferroptosis (in overload states)        | Oxidative stress, mitochondrial dysfunction, ferroptosis, oxygen transport, cellular metabolism, fibrosis |                  |
| **Manganese (Mn)** | Antioxidant (SOD2), enzyme cofactor, glycosylation                                                    | (Rarely studied in CVD context, potential mitochondrial impact)                                          | Neurotoxicity, potential cardiotoxicity at high levels                                              | Oxidative stress (via Nrf2), mitochondrial function                                                  |                  |

*Note: This table provides a simplified overview. The roles and consequences can be complex and context-dependent.*

## **3\. Therapeutic Interventions: Evidence for Modulating Specific Metal Ions**

The potential for correcting metal ion imbalances to prevent or treat CVD has prompted numerous clinical investigations, primarily focusing on supplementation for deficiencies or perceived suboptimal levels, and chelation for overload or toxicity. The strength and consistency of evidence vary considerably among different ions and interventions.

### **3.1. Magnesium (Mg)**

#### **3.1.1. Mechanisms Relevant to Cardiovascular Health**

Magnesium's potential cardiovascular benefits stem from its multifaceted physiological roles. It is essential for mitochondrial ATP production and acts as a mild antioxidant. Mg$^{2+}$ modulates ion transport, acting as a physiological calcium channel blocker and influencing potassium channels, which contributes to vasodilation and stabilization of cardiac rhythm. Low magnesium status is linked mechanistically to increased inflammatory stress (e.g., higher hs-CRP), oxidative stress, endothelial dysfunction, and potentially unfavorable lipid profiles. It may also improve insulin sensitivity.

#### **3.1.2. Clinical Evidence (Supplementation/Dietary Intake)**

Clinical studies and epidemiological data provide a mixed but often supportive picture for magnesium's role in cardiovascular health.

*   **Overall CVD Risk and Mortality:** Meta-analyses of prospective cohort studies consistently demonstrate an inverse association between *circulating* magnesium levels and the risk of total CVD. Higher *dietary* magnesium intake is associated with a significantly lower risk of stroke, heart failure, type 2 diabetes (T2D), and all-cause mortality. Findings for ischemic heart disease (IHD) or coronary heart disease (CHD) are less consistent, with some meta-analyses showing significant inverse associations while others report non-significant trends or no association. One meta-analysis found higher dietary intake linked to lower all-cause and cancer mortality, but not specifically CVD mortality. A non-linear relationship has been observed for dietary magnesium and total CVD events, with the most significant risk reduction seen with intakes increasing up to approximately 400 mg/day compared to lower intakes.
*   **Hypertension:** While low magnesium status is associated with hypertension, specific high-quality evidence from RCTs or meta-analyses focusing solely on magnesium supplementation for blood pressure reduction was not prominently featured in the reviewed materials, although the mechanistic links (vasodilation) are plausible.
*   **Arrhythmias (esp. Atrial Fibrillation - AF):** Low serum magnesium is epidemiologically linked to increased AF risk. Intravenous (IV) magnesium is established as effective prophylaxis against post-operative AF/supraventricular tachycardia (SVT) following cardiac surgery, reducing risk significantly. For acute AF, IV magnesium's role is primarily in rate control, particularly as an adjunct to digoxin, where it enhances ventricular rate reduction (\<100 bpm) compared to digoxin alone. It is less effective for rate control than calcium channel blockers or amiodarone but has a better safety profile regarding bradycardia. Its efficacy for direct cardioversion of acute AF is debated, with meta-analyses yielding conflicting results. IV magnesium is the treatment of choice for Torsades de Pointes and may improve the success of chemical or electrical cardioversion for AF while reducing proarrhythmic risk from certain antiarrhythmics. A pilot RCT demonstrated the feasibility and tolerability (minor GI effects) of oral magnesium oxide (400 mg/day) for potentially preventing AF, showing good adherence, increased serum magnesium levels, and excellent acceptance of rhythm monitoring, supporting the planning of larger prevention trials.
*   **Heart Failure (HF):** Hypomagnesemia is common in HF patients, and observational data link lower dietary magnesium intake to a higher risk of incident HF, particularly among individuals with diabetes. A large observational study emulating a target trial in US veterans with diabetes found that self-reported use of non-prescription magnesium supplements over several years (mean 3.5 years) was associated with a small but statistically significant reduction in the risk of incident HF (HR 0.94) and major adverse cardiac events (MACE; HR 0.94), with benefits appearing after approximately 3 years of use. IV magnesium has also been used to treat ventricular arrhythmias in HF and may offer benefits in acute myocardial infarction (MI) by potentially reducing infarct size, mortality, and arrhythmias, possibly through mechanisms like reducing calcium overload and oxidative stress.
*   **Atherosclerosis/Myocardial Infarction (MI):** Low magnesium status has been associated with coronary artery calcification. While some earlier, smaller meta-analyses suggested mortality and arrhythmia benefits from IV magnesium in acute MI, large landmark trials failed to confirm a clear benefit, potentially due to issues with timing or dosing protocols.

#### **3.1.3. Synthesis**

The collective evidence suggests that maintaining adequate magnesium status, reflected by higher circulating levels or dietary intake, is associated with a lower risk of several major cardiovascular outcomes, particularly stroke, heart failure, and T2D. While the evidence for reducing CHD/total CVD risk through diet is less consistent, the overall pattern is protective. Magnesium supplementation appears feasible for increasing serum levels and is well-established for specific indications like preventing post-operative AF and managing certain ventricular arrhythmias. Its role as an adjunct for rate control in acute AF is supported, offering a safer alternative to more potent agents in some contexts. Emerging evidence suggests potential long-term benefits of supplementation for preventing HF and MACE, especially in high-risk populations like diabetics. However, robust RCT evidence supporting routine supplementation for primary prevention of major CVD events in the general population is still lacking. The discrepancy between strong observational associations and limited primary prevention RCT data underscores the need for further high-quality trials.

**Table 2: Summary of Clinical Evidence for Magnesium Supplementation/Intake and Cardiovascular Outcomes**

| Outcome                                      | Type of Evidence                | Key Findings                                                                                                                                                                                                                            | Relevant Sources |
| :------------------------------------------- | :------------------------------ | :-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | :--------------- |
| Total CVD Events                             | Meta-analysis (Cohorts)         | Inverse association with circulating Mg (RR 0.70 per 0.2 mmol/L). Non-significant association with dietary Mg (RR 0.89 per 200 mg/d). Non-linear inverse association with dietary Mg (greatest benefit up to \~400 mg/d).               |                  |
| Stroke                                       | Meta-analysis (Cohorts)         | Inverse association with dietary Mg (RR 0.93 per 100 mg/d).                                                                                                                                                                             |                  |
| Heart Failure (Incidence)                    | Meta-analysis (Cohorts)         | Inverse association with dietary Mg (RR 0.78 per 100 mg/d).                                                                                                                                                                             |                  |
| Heart Failure (Incidence/MACE in Diabetes)   | Target Trial Emulation (Cohort) | Long-term Mg supplement use associated with lower risk of incident HF (HR 0.94) and MACE (HR 0.94).                                                                                                                                  |                  |
| Ischemic Heart Disease / Coronary Heart Disease | Meta-analysis (Cohorts)         | Inverse association with dietary Mg (RR 0.78 per 200 mg/d). Inconsistent findings across analyses (some non-significant).                                                                                                           |                  |
| Atrial Fibrillation (Post-Op Prevention)     | Meta-analysis (RCTs)            | IV Mg reduces risk of post-op AF/SVT (OR \~0.55).                                                                                                                                                                                       |                  |
| Atrial Fibrillation (Acute Rate Control)     | Meta-analysis (RCTs)            | IV Mg + Digoxin better than Digoxin alone (OR \~3.2). IV Mg less effective than Ca-blockers/Amiodarone (OR \~0.19) but safer re: bradycardia. Modest effect size (\~15 bpm reduction vs placebo).                                          |                  |
| Atrial Fibrillation (Primary Prevention)     | Pilot RCT                       | Oral Mg feasible, well-tolerated, raises serum Mg; supports larger trial.                                                                                                                                                               |                  |
| Ventricular Arrhythmias / TdP                | Clinical Use / Meta-analysis (RCTs in MI) | IV Mg standard for TdP. IV Mg in acute MI associated with reduced VT/VF in some analyses.                                                                                                                                               |                  |
| All-Cause Mortality                          | Meta-analysis (Cohorts)         | Inverse association with dietary Mg (RR 0.90 per 100 mg/d). No significant effect of supplementation in primary prevention RCTs (RR 0.97).                                                                                               |                  |
| CVD Mortality                                | Meta-analysis (Cohorts)         | No significant association with dietary Mg in one analysis. No significant effect of supplementation in primary prevention RCTs (RR 0.97).                                                                                               |                  |
| Type 2 Diabetes                              | Meta-analysis (Cohorts)         | Inverse association with dietary Mg (RR 0.81 per 100 mg/d).                                                                                                                                                                             |                  |

*RR = Relative Risk; HR = Hazard Ratio; OR = Odds Ratio; CI = Confidence Interval.*

### **3.2. Zinc (Zn)**

#### **3.2.1. Mechanisms Relevant to Cardiovascular Health**

Zinc's cardiovascular relevance lies in its roles as an essential cofactor for antioxidant enzymes (e.g., Cu/Zn-SOD), its anti-inflammatory properties, its involvement in insulin signaling and glucose metabolism, and its contribution to maintaining vascular endothelial health. Zinc deficiency is associated with increased oxidative stress, heightened inflammation (increased pro-inflammatory cytokines), endothelial dysfunction, and apoptosis. Zinc also modulates ion channel activity, potentially influencing vascular tone.

#### **3.2.2. Clinical Evidence (Supplementation/Dietary Intake)**

Evidence from clinical trials and observational studies suggests beneficial effects of zinc on cardiovascular risk factors and potentially outcomes.

*   **Cardiometabolic Risk Factors:** A substantial body of evidence from systematic reviews and meta-analyses of RCTs consistently demonstrates that zinc supplementation significantly improves key cardiometabolic risk factors. These benefits include improvements in glycemic control (significant reductions in fasting blood glucose (FBG), Hemoglobin A1c (HbA1c), and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)) and favorable alterations in lipid profiles (significant reductions in triglycerides (TG), total cholesterol (TC), very-low-density lipoprotein (VLDL), and low-density lipoprotein cholesterol (LDL-C), along with increases in high-density lipoprotein cholesterol (HDL-C)). Furthermore, zinc supplementation has been shown to reduce markers of systemic inflammation, including C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). Effects on blood pressure and anthropometric measures (like BMI or waist circumference) have generally been found to be non-significant in these meta-analyses.
*   **CVD Outcomes:** While direct RCT evidence linking zinc supplementation to reduced hard clinical CVD endpoints (MI, stroke, mortality) is limited, observational data are supportive. Lower dietary zinc intake has been associated with a higher prevalence of coronary artery disease (CAD) in a meta-analysis. A prospective cohort study involving patients with T2D found that higher plasma zinc concentrations were significantly associated with a lower risk of incident CVD (HR 0.78 comparing highest to lowest quartile). This study also suggested a synergistic benefit, with individuals having high levels of both zinc and selenium experiencing an even lower CVD risk. Higher plasma zinc levels have also been linked to a reduced risk of mortality from vascular disease in other cohort studies. Mechanistic studies or animal data suggest zinc administration might improve myocardial healing post-injury and reduce arrhythmias.
*   **Dose and Duration Effects:** An interesting finding from one meta-analysis is that the dose and duration of zinc supplementation influence its effects. Low-dose supplementation (\<25 mg/day) significantly improved FBG, insulin resistance, TG, TC, and LDL-C. Long-duration supplementation (≥12 weeks) significantly benefited FBG, TG, TC, and LDL-C. Notably, the effect sizes for low-dose and long-duration interventions appeared to be of equal or even greater magnitude compared to high-dose (≥25 mg/day) or short-duration (\<12 weeks) interventions, suggesting that sustained, lower-level supplementation might be a particularly effective strategy.

#### **3.2.3. Synthesis**

The clinical evidence strongly supports a beneficial role for zinc supplementation in improving a wide range of cardiometabolic risk factors, including glycemic control, lipid profiles, and inflammation markers. These effects are consistently observed across multiple meta-analyses of RCTs. Observational studies further link higher zinc status or intake with a lower risk of developing CVD, especially in individuals with T2D. The finding that lower doses sustained over longer periods may be particularly effective is noteworthy, suggesting potential relevance for strategies like food fortification or long-term supplementation in at-risk populations. While the translation of these risk factor improvements into proven reductions in hard clinical outcomes requires confirmation from large-scale, long-term RCTs, the existing evidence points towards a potentially significant role for maintaining adequate zinc status in cardiovascular prevention, particularly given its antioxidant and anti-inflammatory properties. The gap between strong evidence for improving surrogate markers and less direct evidence for clinical outcome reduction remains a key area for future research, a common challenge in evaluating nutritional interventions.

**Table 3: Summary of Clinical Evidence for Zinc Supplementation on Cardiometabolic Risk Factors and CVD Risk**

| Outcome/Marker                    | Type of Evidence           | Key Findings (Supplementation vs. Placebo/Control)                                                              | Relevant Sources |
| :-------------------------------- | :------------------------- | :-------------------------------------------------------------------------------------------------------------- | :--------------- |
| Fasting Blood Glucose (FBG)       | Meta-analysis (RCTs)       | Significantly decreased (SMD \~ -0.52; WMD \~ -19.66 mg/dL)                                                       |                  |
| Hemoglobin A1c (HbA1c)            | Meta-analysis (RCTs)       | Significantly decreased (SMD \~ -0.64; WMD \~ -0.43 mg/dL)                                                       |                  |
| Insulin Resistance (HOMA-IR)      | Meta-analysis (RCTs)       | Significantly decreased                                                                                         |                  |
| Triglycerides (TG)                | Meta-analysis (RCTs)       | Significantly decreased (SMD \~ -0.66)                                                                          |                  |
| Total Cholesterol (TC)            | Meta-analysis (RCTs)       | Significantly decreased (SMD \~ -0.65; WMD \~ -18.51 mg/dL)                                                       |                  |
| LDL Cholesterol (LDL-C)           | Meta-analysis (RCTs)       | Significantly decreased (WMD \~ -4.80 mg/dL)                                                                    |                  |
| HDL Cholesterol (HDL-C)           | Meta-analysis (RCTs)       | Significantly increased (WMD \~ 1.45 mg/dL)                                                                     |                  |
| VLDL Cholesterol                  | Meta-analysis (RCTs)       | Significantly decreased (SMD \~ -1.59)                                                                          |                  |
| C-Reactive Protein (CRP)          | Meta-analysis (RCTs)       | Significantly decreased                                                                                         |                  |
| Interleukin-6 (IL-6)              | Meta-analysis (RCTs)       | Significantly decreased                                                                                         |                  |
| Tumor Necrosis Factor-α (TNF-α)   | Meta-analysis (RCTs)       | Significantly decreased                                                                                         |                  |
| Blood Pressure / Anthropometrics  | Meta-analysis (RCTs)       | No significant effect                                                                                           |                  |
| Incident CVD Risk (in T2D)        | Prospective Cohort         | Inverse association with plasma Zn (HR \~0.78, Q4 vs Q1). Combined high Zn+Se further reduced risk.                 |                  |
| Coronary Artery Disease (CAD) Prevalence | Meta-analysis (Observational) | Inverse association with dietary Zn intake.                                                                     |                  |
| Vascular Disease Mortality        | Cohort Studies             | Inverse association with plasma Zn.                                                                             |                  |

*SMD = Standardized Mean Difference; WMD = Weighted Mean Difference; HR = Hazard Ratio; Q = Quartile.*

### **3.3. Selenium (Se)**

#### **3.3.1. Mechanisms Relevant to Cardiovascular Health**

Selenium's primary cardiovascular relevance stems from its incorporation into essential antioxidant enzymes, particularly glutathione peroxidases (GPx), which protect cells from oxidative damage. Severe selenium deficiency is known to cause Keshan disease, a form of cardiomyopathy endemic to certain regions of China, highlighting its essentiality for cardiac health. However, selenium can also exhibit pro-oxidant properties at higher concentrations, contributing to the controversy surrounding its optimal intake range.

#### **3.3.2. Clinical Evidence (Supplementation/Dietary Intake)**

Despite the mechanistic rationale and the clear detriment of severe deficiency, evidence regarding selenium supplementation for preventing CVD in populations with adequate intake is largely negative.

*   **Primary CVD Prevention:** Multiple iterations of Cochrane systematic reviews and meta-analyses, representing the highest level of evidence synthesis for RCTs, have consistently concluded that selenium-only supplementation does **not** significantly affect the incidence of major cardiovascular events (fatal or non-fatal), CVD mortality, or all-cause mortality in individuals initially free from CVD. These conclusions are primarily based on large trials conducted in populations, mainly US males, presumed to have adequate or high baseline selenium intake from their diet.
*   **CVD Risk Factors:** The effect of selenium supplementation on traditional CVD risk factors appears minimal or inconsistent based on available RCT data. Meta-analyses found no significant changes in HDL cholesterol levels. While some analyses showed non-significant trends towards lower total cholesterol or a statistically significant reduction in non-HDL cholesterol in one trial with varying doses, these findings are not robust. Effects on blood pressure were not examined in the longer-term trials included in the Cochrane reviews.
*   **Type 2 Diabetes (T2D) Risk:** A significant concern that emerged from large trials like SELECT (Selenium and Vitamin E Cancer Prevention Trial) and subsequent meta-analyses is the potential for selenium supplementation (typically 200 µg/day) to *increase* the risk of developing T2D, particularly in individuals already replete with selenium. While the pooled relative risk estimate in meta-analyses often borders statistical significance (RR around 1.06, 95% CI spanning 0.97-1.15/1.16), this potential adverse effect warrants caution and requires further clarification. Other adverse effects noted in the SELECT trial included increased rates of alopecia and mild dermatitis.
*   **Observational Data:** Epidemiological studies investigating the link between selenium status (measured in blood or toenails) and CVD risk have yielded inconsistent results. Some studies, particularly in populations with lower baseline selenium levels, suggested an inverse association. However, more recent evidence often points towards a U-shaped relationship, where both low and high selenium status might be associated with increased risk. In contrast to the null findings in primary prevention trials, one prospective cohort study in patients with existing T2D found that higher plasma selenium levels were associated with a *lower* risk of incident CVD.

#### **3.3.3. Synthesis**

Based on the current high-quality evidence from RCTs, predominantly synthesized in Cochrane reviews, routine selenium supplementation cannot be recommended for the primary prevention of cardiovascular disease in individuals who are already well-nourished and have adequate baseline selenium levels. In such populations, supplementation appears to offer no significant cardiovascular benefit and may carry a potential risk of increasing the incidence of T2D, alongside minor dermatological side effects. The discrepancy between these RCT findings and some observational data (like the protective association seen in diabetics) highlights potential limitations of observational studies (confounding) or suggests that the effects of selenium might be highly dependent on the baseline status and specific population characteristics (e.g., presence of T2D). While selenium is undeniably essential and deficiency leads to cardiomyopathy, supplementation beyond ensuring adequacy does not appear beneficial for cardiovascular health in most Western populations and should be approached with caution due to the potential diabetogenic effect. Future research might focus on the role of selenium in demonstrably deficient populations or specific patient subgroups, but widespread supplementation for CVD prevention is not currently supported.

**Table 4: Summary of Clinical Evidence from Cochrane Reviews for Selenium Supplementation (Primary Prevention in Generally Replete Populations)**

| Outcome                             | Type of Evidence       | Key Findings (Supplementation vs. Placebo)                                | Certainty of Evidence   | Relevant Sources |
| :---------------------------------- | :--------------------- | :------------------------------------------------------------------------ | :---------------------- | :--------------- |
| All-Cause Mortality                 | Meta-analysis (RCTs)   | No significant effect (RR 0.97, 95% CI 0.88-1.08)                         | Moderate/High           |                  |
| CVD Mortality                       | Meta-analysis (RCTs)   | No significant effect (RR 0.97, 95% CI 0.79-1.20)                         | Moderate/High           |                  |
| Non-Fatal CVD Events                | Meta-analysis (RCTs)   | No significant effect (RR 0.96, 95% CI 0.89-1.04)                         | Moderate/High           |                  |
| All CVD Events (Fatal + Non-Fatal)  | Meta-analysis (RCTs)   | No significant effect (RR 1.03, 95% CI 0.95-1.11)                         | Moderate/High           |                  |
| Type 2 Diabetes Incidence           | Meta-analysis (RCTs)   | Small increased risk, borderline significance (RR 1.06, 95% CI 0.97-1.15/1.16) | Moderate (concern noted) |                  |
| Total Cholesterol                   | Meta-analysis (RCTs)   | No significant effect (WMD -0.11 mmol/L, 95% CI -0.30 to 0.07)             | Low                     |                  |
| HDL Cholesterol                     | Meta-analysis (RCTs)   | No significant effect                                                     | Low                     |                  |
| Non-HDL Cholesterol                 | Single Trial (Varying Dose) | Statistically significant reduction (WMD -0.2 mmol/L, 95% CI -0.41 to 0.00) | Very Low                |                  |
| Alopecia / Dermatitis               | Single Large Trial (SELECT) | Increased risk with supplementation (RR \~1.2-1.3)                        | Moderate                |                  |

*RR = Relative Risk; CI = Confidence Interval; WMD = Weighted Mean Difference. Certainty of evidence interpretation based on review conclusions.*

### **3.4. Copper (Cu)**

#### **3.4.1. Mechanisms Relevant to Cardiovascular Health**

Copper is integral to cardiovascular function through its role as a cofactor in enzymes governing mitochondrial energy production (CcO), antioxidant defense (SOD1), connective tissue integrity (lysyl oxidase), and iron metabolism (ceruloplasmin). It also plays a role in promoting angiogenesis. Copper deficiency can severely impair mitochondrial function, leading to compensatory cardiac hypertrophy and heart failure in animal models and potentially contributing to ischemic heart disease. Conversely, copper excess is toxic, promoting oxidative stress, mitochondrial damage, endothelial dysfunction, and potentially contributing to atherosclerosis, arrhythmias, and cardiomyopathy. A specific form of copper-induced cell death, termed cuproptosis, has been increasingly recognized as relevant in cardiovascular pathologies.

#### **3.4.2. Clinical Evidence**

The clinical evidence linking copper status to cardiovascular health is complex and often contradictory, partly due to challenges in accurately assessing copper status and differentiating between dietary intake and circulating levels.

*   **Dietary Intake vs. Serum Levels:** A critical point is that serum copper levels may not reliably reflect dietary copper intake or total body copper status. Copper absorption is influenced by various factors (age, gender, other dietary components like zinc), and serum copper levels can increase during inflammatory states (as ceruloplasmin is an acute phase reactant), potentially confounding associations with CVD, which often involves inflammation.
*   **Myocardial Infarction (MI):** Evidence regarding copper and MI risk is conflicting. A large analysis of NHANES data found that higher *dietary* copper intake was associated with a significantly *lower* risk of self-reported MI, with a non-linear dose-response relationship. This protective association appeared stronger in specific subgroups like elderly women, overweight individuals, smokers, and those with hypertension or diabetes. In stark contrast, a meta-analysis of observational studies focusing on *serum* copper levels found that higher S-Cu concentrations were associated with a significantly *increased* risk of MI (pooled OR 1.31), as well as total stroke and cardiovascular mortality. Some studies measuring serum metals in post-MI patients also found high copper concentrations significantly increased the odds of having had an MI.
*   **Atherosclerosis and Other CVDs:** Mechanistic and animal studies implicate copper dysregulation (both deficiency and excess) in the pathogenesis of atherosclerosis, arrhythmias, and cardiomyopathy. The meta-analysis linking high serum copper to increased MI risk also found an increased risk for total stroke (pooled OR 1.49) and cardiovascular mortality (pooled OR 1.60). Copper deficiency is clearly linked to cardiac hypertrophy and failure in experimental models.
*   **Interventions:** Therapeutic interventions primarily focus on managing copper dysregulation rather than general CVD prevention. Copper chelating agents are the mainstay treatment for copper overload conditions like Wilson's disease, aiming to prevent systemic toxicity, including potential cardiac complications. Copper supplementation has shown benefit in animal models of copper deficiency-induced cardiomyopathy, reversing hypertrophy and improving function, but clinical evidence for supplementation in human CVD outside of deficiency states is lacking. Copper ion carriers are proposed as an alternative delivery method but face technical limitations.

#### **3.4.3. Synthesis**

Copper homeostasis presents a paradoxical relationship with cardiovascular health based on current evidence. Higher dietary copper intake appears protective against MI in a large observational study, aligning with the known essentiality of copper for cardiac function and the detrimental effects of deficiency seen in experimental models. However, multiple observational studies and meta-analyses consistently link higher *serum* copper levels to an *increased* risk of MI, stroke, and cardiovascular mortality. This striking discrepancy likely reflects the limitations of serum copper as a biomarker of nutritional status, potentially being elevated due to inflammation or other factors associated with CVD risk, rather than dietary excess itself being the primary driver of risk in most cases. Both copper deficiency and copper overload are clearly detrimental to the cardiovascular system. Given this complexity and the narrow therapeutic window for copper, interventions involving copper modulation (supplementation or chelation) should be strictly limited to cases of diagnosed deficiency or overload (like Wilson's disease), respectively. Routine modulation of copper levels for general cardiovascular prevention is not supported by current evidence and requires careful consideration due to the potential for harm from either inadequate or excessive levels. Further research is needed to clarify the true relationship between dietary copper, functional copper status, and CVD risk, potentially using better biomarkers than serum copper alone.

### **3.5. Iron (Fe) Management in Cardiovascular Disease**

Iron homeostasis is critically important in cardiovascular health, with both deficiency and overload having significant pathological consequences, particularly in the context of heart failure.

#### **3.5.1. Iron Deficiency (ID) in Heart Failure (HF)**

*   **Prevalence and Definition:** Iron deficiency is remarkably common in patients with HF, affecting approximately 37-50% of those with chronic HF and potentially 60-80% of patients hospitalized with acute HF exacerbations. Importantly, ID frequently occurs even in the absence of anemia (low hemoglobin). The most widely accepted definition of ID in HF, used in major clinical trials and endorsed by guidelines, is a serum ferritin level \<100 µg/L (absolute ID) OR a serum ferritin level between 100-299 µg/L combined with a transferrin saturation (TSAT) \<20% (functional ID).
*   **Diagnosis Challenges:** Diagnosing ID in HF using these criteria is not without challenges. Serum ferritin is an acute phase reactant, meaning its levels can be elevated by the systemic inflammation often present in HF, potentially masking underlying absolute ID. Consequently, the ferritin/TSAT criteria may not perfectly correlate with gold-standard bone marrow iron stores; some suggest that TSAT \<20% combined with a low serum iron level (\<13 µg/dL) might be a stronger indicator of true deficiency in this population. Furthermore, serum iron indices can fluctuate significantly over time in HF patients, sometimes normalizing even without specific iron therapy, although persistent ID is associated with worse outcomes. These diagnostic complexities highlight the need for potentially better or complementary biomarkers, such as soluble transferrin receptor (sTFR), although these are not yet widely validated or used in HF guidelines.
*   **Pathophysiology and Prognosis:** The causes of ID in HF are multifactorial, including inadequate dietary intake, malabsorption due to gut edema and inflammation-driven increases in hepcidin (which blocks iron absorption and release), gastrointestinal blood loss (often related to antiplatelet or anticoagulant use), and potentially impaired cellular iron uptake. Iron is essential not only for hemoglobin synthesis and oxygen transport but also for myoglobin (muscle oxygen storage) and numerous mitochondrial enzymes involved in cellular energy production (oxidative phosphorylation). Therefore, ID, even without anemia, directly impairs cardiac and skeletal muscle energetics and function, contributing significantly to hallmark HF symptoms like fatigue, dyspnea, and reduced exercise capacity. Clinically, ID is associated with greater HF severity (higher NYHA functional class, elevated NT-proBNP levels) and serves as a strong, independent predictor of increased risk for all-cause mortality and HF hospitalizations.

#### **3.5.2. Iron Supplementation in Heart Failure**

Given the high prevalence and adverse prognostic implications of ID in HF, iron repletion has become a key therapeutic target.

*   **Guideline Recommendations:** Major cardiology guidelines from the European Society of Cardiology (ESC) and the American Heart Association/American College of Cardiology/Heart Failure Society of America (AHA/ACC/HFSA) recommend screening HF patients for anemia and ID using serum ferritin and TSAT. They specifically recommend intravenous (IV) iron supplementation (primarily using ferric carboxymaltose, FCM) for symptomatic patients with HF with reduced ejection fraction (HFrEF; LVEF ≤40%) or mildly reduced EF (HFmrEF; LVEF 41-49%) and documented ID (using the standard definition). The goals of IV iron therapy are to improve functional status (exercise capacity), quality of life (QoL), and reduce HF hospitalizations. The strength of recommendation varies slightly, with ESC assigning Class I (strongest recommendation) or IIa (should be considered) depending on the specific context (chronic vs. acute HF), while the 2022 AHA/ACC/HFSA guideline assigns a Class 2a recommendation. Despite these clear recommendations, studies indicate that screening and treatment practices for ID in HF often fall short in routine clinical care, representing a significant gap.
*   **Intravenous (IV) Iron Evidence (RCTs & Meta-Analyses):** The guideline recommendations are underpinned by a series of important RCTs and subsequent meta-analyses.
    *   *Hospitalizations:* A consistent finding across multiple moderate-to-large RCTs (including FAIR-HF, CONFIRM-HF, EFFECT-HF, AFFIRM-AHF, IRONMAN) and numerous meta-analyses is that IV iron administration (using FCM or ferric derisomaltose) significantly reduces the risk of hospitalizations due to worsening HF compared to placebo or standard care. Meta-analyses typically report relative risk reductions of 25-50% for HF hospitalizations or composite endpoints predominantly driven by hospitalizations. This benefit appears robust across different clinical settings (chronic stable HF, recently decompensated HF) and potentially greater in patients with lower baseline TSAT (\<20%).
    *   *Mortality:* In contrast to the clear benefit on hospitalizations, the effect of IV iron on mortality (cardiovascular or all-cause) remains inconclusive. Major individual trials like AFFIRM-AHF, IRONMAN, and HEART-FID did not demonstrate a statistically significant reduction in their primary composite endpoints that included mortality, although external factors like the COVID-19 pandemic impacted some trials. Consequently, meta-analyses consistently show no significant difference in CV or all-cause mortality between IV iron and control groups.
    *   *Functional Status and Quality of Life (QoL):* Earlier trials like FAIR-HF and CONFIRM-HF, as well as EFFECT-HF, clearly demonstrated that IV iron improves patient symptoms, functional capacity (e.g., 6-minute walk distance), NYHA functional class, and overall QoL scores. These improvements in patient-centered outcomes are a key rationale for the guideline recommendations.
    *   *Safety:* IV iron has generally been well-tolerated in clinical trials. However, potential concerns exist. Infusion reactions can occur. By bypassing the normal physiological regulation of iron absorption mediated by hepcidin, IV iron administration could theoretically lead to transiently high levels of non-transferrin-bound iron, potentially generating oxidative stress and endothelial damage, although clinical evidence for harm is limited. There is also a potential risk of hypophosphatemia and a theoretical, debated risk of increased susceptibility to infection compared to oral iron. Current trials lack sufficient long-term safety data.
*   **Oral Iron Evidence:** Oral iron supplementation is generally considered ineffective and is not recommended for treating ID in HF patients. This is primarily due to poor and unreliable gastrointestinal absorption, which is often further impaired by gut edema and the inflammatory state (high hepcidin levels) characteristic of HF. Additionally, oral iron preparations are frequently associated with significant GI side effects (e.g., constipation, nausea, abdominal pain), leading to poor adherence. Clinical trials using various oral iron formulations in HF have shown inconsistent and generally minimal effects on iron status or clinical outcomes. The small IRON-HF trial, which compared IV iron, oral iron, and placebo, found significant improvement in peak oxygen consumption only in the IV iron group. While newer oral formulations like sucrosomial iron are being developed with claims of better absorption and tolerability, they currently lack robust evidence from large HF clinical trials. The clear difference in efficacy between IV and oral iron in HF underscores how the delivery route and formulation can be critical determinants of therapeutic success, especially when physiological barriers like impaired absorption exist.

#### **3.5.3. Iron Overload and Cardiovascular Risk**

While ID is detrimental in HF, iron overload is also harmful to the heart. Conditions leading to systemic iron overload, such as hereditary hemochromatosis or transfusion-dependent anemias (e.g., β-thalassemia), result in excessive iron deposition in various organs, including the myocardium. Cardiac iron accumulation leads to mitochondrial dysfunction, increased oxidative stress, impaired myocardial contractility, fibrosis, arrhythmias, and ultimately, potentially fatal heart failure. Furthermore, ferroptosis, an iron-dependent form of regulated cell death characterized by lipid peroxidation, has been implicated in the pathophysiology of various CVDs, including iron-overload cardiomyopathy, atherosclerosis, and myocardial ischemia-reperfusion injury.

#### **3.5.4. Synthesis**

Iron metabolism plays a critical, dual role in cardiovascular health. Iron deficiency is a highly prevalent and clinically significant comorbidity in heart failure, contributing to symptoms, reduced functional capacity, and increased risk of hospitalization and mortality. Intravenous iron therapy, particularly with ferric carboxymaltose, is now a guideline-recommended treatment for symptomatic HFrEF and HFmrEF patients with documented ID, based on robust evidence demonstrating improvements in symptoms, QoL, and a significant reduction in HF hospitalizations. However, a definitive mortality benefit has not been established. Challenges remain in optimizing the diagnosis of ID in the inflammatory milieu of HF. Oral iron therapy is considered ineffective due to poor absorption and tolerability. Conversely, iron overload is clearly cardiotoxic, causing cardiomyopathy and contributing to HF. This underscores the critical importance of maintaining iron homeostasis, avoiding both deficiency and excess. Therapeutic strategies must be tailored based on accurate assessment of iron status.

**Table 5: Summary of Key Randomized Controlled Trials (RCTs) for IV Iron in Heart Failure**

| Trial Acronym | Patient Population                                                                    | Intervention (IV Iron)   | Comparator    | Primary Endpoint(s)                                            | Key Results                                                                                                | Relevant Sources |
| :------------ | :------------------------------------------------------------------------------------ | :----------------------- | :------------ | :------------------------------------------------------------- | :--------------------------------------------------------------------------------------------------------- | :--------------- |
| **FAIR-HF** (2009) | Chronic HF (NYHA II/III, LVEF ≤40-45%), ID (Ferritin \<100 or 100-299 + TSAT \<20%), Hb 9.5-13.5 g/dL | Ferric Carboxymaltose (FCM) | Placebo       | Self-reported Patient Global Assessment (PGA) & NYHA class at 24 wks | Improved PGA (OR 2.51), Improved NYHA class                                                                |                  |
| **CONFIRM-HF** (2015) | Chronic HF (NYHA II/III, LVEF ≤45%), ID (Ferritin \<100 or 100-299 + TSAT \<20%), Hb ≤15 g/dL | FCM                      | Placebo       | Change in 6-min walk test (6MWT) distance at 24 wks            | Improved 6MWT distance, Improved NYHA/PGA/QoL, Reduced HF hospitalizations (secondary)                     |                  |
| **EFFECT-HF** (2017) | Chronic HF (NYHA II/III, LVEF ≤45%), ID (Ferritin \<100 or 100-299 + TSAT \<20%), Hb 9-14 g/dL | FCM                      | Standard Care | Change in peak VO2 at 24 wks                                   | No significant difference in peak VO2; Improved 6MWT, NYHA, QoL                                            |                  |
| **AFFIRM-AHF** (2021) | Acute HF hospitalization (LVEF \<50%), ID (Ferritin \<100 or 100-299 + TSAT \<20%), Hb 8-15 g/dL | FCM                      | Placebo       | Total HF hospitalizations & CV death up to 52 wks              | Reduced total HF hospitalizations; No significant difference in composite endpoint or CV death (trial impacted by COVID-19) |                  |
| **IRONMAN** (2022) | Chronic HF (LVEF ≤45%, NYHA II-IV) or recent HF hospitalization, ID (Ferritin \<100 or TSAT \<20%) | Ferric Derisomaltose     | Usual Care    | Recurrent HF hospitalizations & CV death                       | Reduced composite endpoint (borderline significance, RR 0.82, p=0.07); Reduced HF hospitalizations; No difference in CV death (trial impacted by COVID-19) |                  |
| **HEART-FID** (2023) | Chronic HF (LVEF ≤40%, NYHA II-IV), ID (Ferritin \<100 or 100-300 + TSAT \<20%)         | FCM                      | Placebo       | Hierarchical: Death, HF hospitalizations at 12 mo, change in 6MWT | Negative for primary endpoint; No significant difference in components                                     |                  |

*ID = Iron Deficiency; LVEF = Left Ventricular Ejection Fraction; NYHA = New York Heart Association; TSAT = Transferrin Saturation; Hb = Hemoglobin; FCM = Ferric Carboxymaltose; 6MWT = 6-Minute Walk Test; QoL = Quality of Life; CV = Cardiovascular; VO2 = Oxygen Consumption; RR = Rate Ratio; OR = Odds Ratio.*

## **4\. Chelation Therapy in Cardiovascular Disease**

Chelation therapy involves the administration of agents that bind to metal ions, forming stable, soluble complexes that can then be excreted from the body, thereby reducing metal burden. While its established use is in treating toxic metal overload, its application has controversially been extended to common cardiovascular conditions like atherosclerosis.

### **4.1. Rationale and Targeted Ions**

The rationale for using chelation in CVD varies depending on the target ion:

*   **Heavy Metals (Lead, Cadmium, Mercury, Arsenic):** Given the epidemiological evidence linking chronic exposure to these environmental pollutants with increased CVD risk (hypertension, atherosclerosis, MI), potentially mediated by oxidative stress and inflammation, chelation therapy is proposed as a means to reduce the body's toxic metal load and consequently lower cardiovascular risk. Agents like disodium edetate (EDTA) can bind these divalent and trivalent cations.
*   **Calcium (Ca):** A historical and prominent rationale for using EDTA chelation in atherosclerosis was the hypothesis that by binding and removing calcium, it could reduce or reverse the calcification of atherosclerotic plaques, thereby improving blood flow.
*   **Iron (Fe):** Iron chelation is the standard of care for managing iron overload resulting from conditions like transfusion-dependent thalassemia or hereditary hemochromatosis. The goal is to prevent or treat iron deposition in vital organs, particularly the heart, thus preventing iron-induced cardiomyopathy and heart failure. Specific iron chelators include deferoxamine (injectable), deferiprone (oral), and deferasirox (oral). Mechanistically, iron chelation is also explored for its potential to mitigate iron-catalyzed oxidative stress and ferroptosis in other CVD contexts like ischemia-reperfusion injury.
*   **Copper (Cu):** Copper chelation therapy is employed in conditions of copper overload, most notably Wilson's disease, to prevent copper accumulation and toxicity in organs including the liver, brain, and potentially the heart.

### **4.2. EDTA Chelation for Atherosclerosis**

The use of IV disodium EDTA chelation for treating and preventing atherosclerotic cardiovascular disease has been widespread in complementary and alternative medicine circles for decades but remains highly controversial and lacks approval from regulatory bodies like the FDA.

*   **Trial to Assess Chelation Therapy (TACT):** To address the controversy with rigorous evidence, the US National Institutes of Health (NIH) sponsored the TACT trial.
    *   *TACT1:* This large-scale (n=1708), randomized, placebo-controlled trial enrolled patients with a prior MI. It found a statistically significant, albeit modest, reduction in the primary composite endpoint (all-cause mortality, recurrent MI, stroke, coronary revascularization, or hospitalization for angina) over a median follow-up of 55 months (HR 0.82, 95% CI 0.69-0.99, p=0.035). A pre-specified subgroup analysis suggested a more pronounced benefit among patients with diabetes. However, the trial faced criticism regarding methodology (e.g., high participant withdrawal rate, use of a complex infusion solution alongside EDTA, potential unblinding issues). The TACT investigators themselves concluded that the results, while statistically significant, were unexpected and did not provide sufficient evidence to support the *routine* use of EDTA chelation therapy for post-MI patients.
    *   *TACT2:* Based on the subgroup findings of TACT1, a second trial (TACT2) was funded and is ongoing, specifically focusing on the efficacy of EDTA chelation in post-MI patients *with* diabetes.
*   **Systematic Reviews and Meta-Analyses:** Prior to TACT, systematic reviews consistently concluded there was a lack of convincing evidence for the efficacy of EDTA chelation beyond a potential placebo effect, often relying on case series or small, flawed trials. Reviews published after TACT incorporate its findings but generally maintain a cautious stance. They acknowledge the statistically significant result but emphasize the modest effect size, trial limitations, and the remaining uncertainty. A 2020 Cochrane review concluded that the overall certainty of evidence remains low to very low due to the paucity of high-quality data and risk of bias in studies preceding TACT, making it impossible to draw firm conclusions about effectiveness. One systematic review focusing on clinical outcomes identified 24 studies (including TACT and many non-RCTs) and noted that 17 suggested improved outcomes, particularly in patients with diabetes or severe peripheral arterial disease (PAD); a small meta-analysis within this review indicated a statistically significant improvement in ankle-brachial index (ABI) in PAD patients.
*   **Safety:** TACT and subsequent reviews suggest that EDTA chelation, when administered according to protocol (slow infusion, adequate hydration, monitoring renal function), has a relatively low risk of serious adverse events. Hypocalcemia is a known potential risk but was infrequent in TACT. The primary safety concern often raised is the potential for indirect harm if patients choose chelation therapy *instead* of evidence-based, proven treatments for CVD (like statins, antiplatelets, revascularization), thereby delaying or foregoing effective care.
*   **Synthesis:** Despite the large TACT1 trial demonstrating a statistically significant reduction in a composite endpoint, EDTA chelation therapy for the general treatment or prevention of atherosclerosis remains controversial and is not recommended for routine clinical practice by major medical organizations. The modest effect size, methodological concerns surrounding TACT1, and the consistently cautious conclusions of systematic reviews indicate that the evidence base is insufficient to justify its widespread use. The potential for benefit specifically in diabetic patients post-MI is being further investigated in TACT2. The persistence of EDTA chelation in alternative medicine settings, often based on lower-quality evidence or anecdotal claims, underscores the importance of adhering to rigorous evidence standards derived from well-conducted RCTs and systematic reviews when evaluating any therapeutic modality. The gap between the plausible mechanistic rationale (removing metals/calcium) and the demonstrated clinical benefit for atherosclerosis remains significant, suggesting either the targeted mechanism is less critical than hypothesized or the intervention itself has limitations in achieving clinically meaningful effects in this broad context.

**Table 6: Summary of Key Evidence for EDTA Chelation Therapy in Atherosclerotic Cardiovascular Disease**

| Study Type / Key Study                               | Patient Population                                       | Primary Outcome(s) Assessed                                             | Key Efficacy Findings                                                                                                             | Key Safety Findings                                                    | Overall Conclusion/Certainty                                                                                    | Relevant Sources |
| :--------------------------------------------------- | :------------------------------------------------------- | :---------------------------------------------------------------------- | :-------------------------------------------------------------------------------------------------------------------------------- | :--------------------------------------------------------------------- | :-------------------------------------------------------------------------------------------------------------- | :--------------- |
| **RCT / TACT1** (Lamas et al., 2013/2014)             | Post-MI (n=1708), Age ≥50                                | Composite: All-cause death, MI, stroke, revascularization, angina hospitalization | Statistically significant reduction (HR 0.82, p=0.035). Benefit appeared greater in diabetic subgroup.                               | Generally safe; no significant increase in serious adverse events vs placebo. | Results do not support *routine* use; modest effect, trial limitations noted.                                     |                  |
| **Systematic Review / Cochrane** (Villarruz et al., 2020) | Atherosclerotic CVD (5 RCTs, n=1993, incl. TACT1)        | All-cause mortality, CV death, MI, stroke, revascularization, ABI, walking distance, QoL | No significant difference for most outcomes (mortality, MI, stroke, angina, revasc., walking distance). ABI findings mixed/biased. QoL inconclusive. | No evidence of major adverse events.                                   | Insufficient evidence to determine effectiveness; low to very low certainty of evidence. More high-quality RCTs needed. |                  |
| **Systematic Review / Meta-Analysis** (Lamas et al. / Ujueta et al., 2022) | CVD (24 studies, 4 RCTs, incl. TACT1)                    | Mortality, disease severity, biomarkers, QoL, ABI                       | 17/24 studies suggested improvement (mostly non-RCTs). Meta-analysis (4 studies) showed small ABI improvement (0.08). Benefit suggested greater in diabetes/severe PAD. | -                                                                      | Repeated EDTA *may* benefit patients with diabetes/severe PAD; more research needed.                               |                  |
| **Narrative Review** (Anand et al., 2017)            | CVD                                                      | CV outcomes, safety                                                     | TACT results encouraging but insufficient for routine use, even in diabetics (pending TACT2).                                     | Potential adverse effects; harm if used instead of proven therapies.   | Avoid unsubstantiated claims; evidence inadequate for efficacy.                                                 |                  |
| **Systematic Review** (Seely et al., 2005 - Pre-TACT) | CVD (5 RCTs prior to TACT)                               | CV outcomes                                                             | 2 smaller studies showed benefit, 3 showed no benefit.                                                                            | Rare hypocalcemia, one case increased creatinine.                      | Evidence does not support therapeutic use for CVD.                                                                |                  |
| **Systematic Review** (Ernst, 2000 - Pre-TACT)        | Coronary Heart Disease (Clinical investigations)         | Efficacy                                                                | Numerous case reports/series suggest benefit. Only 2 controlled trials found, providing no evidence beyond placebo.             | Potential for severe adverse effects.                                  | Treatment should be considered obsolete.                                                                        |                  |

*HR = Hazard Ratio; OR = Odds Ratio; ABI = Ankle-Brachial Index; QoL = Quality of Life; PAD = Peripheral Artery Disease.*

### **4.3. Iron and Copper Chelation: Specific Clinical Applications**

In contrast to the controversy surrounding EDTA for atherosclerosis, chelation therapy has well-defined and evidence-based roles in managing specific metal overload conditions.

*   **Iron Chelation:** This is a cornerstone of management for patients with transfusion-dependent β-thalassemia and other conditions leading to chronic iron overload. Regular blood transfusions lead to progressive iron accumulation, particularly in the liver and heart. Cardiac iron deposition causes a toxic cardiomyopathy that was the leading cause of death in these patients before effective chelation therapy became available. Iron chelators (deferoxamine, deferiprone, deferasirox) bind excess iron, promoting its excretion and preventing or reversing cardiac iron loading. A systematic review and meta-analysis confirmed that iron chelators significantly reduce myocardial iron content (assessed by cardiac MRI T2\*) in thalassemia patients, although no significant difference in efficacy between deferoxamine and deferiprone was found for this outcome. Effective chelation therapy, often guided by MRI monitoring of cardiac iron levels, is crucial for improving cardiac function (LVEF) and dramatically improving survival in these patients. Beyond thalassemia, iron chelation is being explored as a potential strategy to mitigate iron-mediated injury in other contexts, such as reducing ferroptosis in ischemia-reperfusion injury or other conditions associated with localized iron dysregulation.
*   **Copper Chelation:** This is the standard treatment for Wilson's disease, an inherited disorder of copper metabolism leading to toxic copper accumulation in the liver, brain, eyes, and other tissues, potentially including the heart. Chelating agents like penicillamine or trientine bind excess copper, promoting its urinary excretion and preventing organ damage. Effective chelation is essential for managing the systemic manifestations of Wilson's disease.
*   **Heavy Metal Chelation:** While the link between environmental heavy metal exposure (Pb, Cd, Hg, As) and increased CVD risk is increasingly recognized, the clinical evidence specifically supporting chelation therapy (e.g., using EDTA or other agents like dimercaptosuccinic acid - DMSA) for *preventing* cardiovascular events by reducing body burden in chronically exposed individuals appears less developed compared to the specific indications for iron or copper chelation. Some sources suggest chelation, possibly combined with antioxidant supplements (like Se, Zn, vitamins), as a potential strategy to diminish the CVD burden attributable to metal exposure, but large-scale trial data focusing on CVD outcomes seem limited based on the reviewed materials. The TACT trial's hypothesis partly involved removing lead and cadmium, potentially contributing to the observed effect.

The clear distinction in the strength of evidence and clinical acceptance between iron/copper chelation for specific overload diseases and EDTA chelation for the broad indication of atherosclerosis highlights that "chelation therapy" is not a single entity. Its value and validity must be assessed based on the specific chelator used, the metal targeted, and the precise clinical context or disease state being addressed.

## **5\. Underlying Biological Mechanisms of Metal Ion Modulation**

The potential therapeutic effects of modulating metal ion concentrations in CVD stem from their influence on fundamental biological pathways implicated in cardiovascular health and disease. Understanding these mechanisms provides a rationale for intervention and may guide the development of more targeted strategies.

### **5.1. Impact on Redox Balance, Inflammation, and Endothelial Function**

A central node through which metal ions influence cardiovascular health is the intricate interplay between redox balance, inflammation, and endothelial function.

*   **Redox Balance:** Modulating metal ions can significantly impact cellular redox state. Supplementation with essential minerals that serve as cofactors for antioxidant enzymes—such as magnesium, manganese (for SOD2), zinc (for SOD1/3, metallothioneins), selenium (for GPx), and copper (for SOD1)—can bolster the endogenous antioxidant defense system, helping to neutralize excessive ROS. For instance, manganese can activate the Keap1-Nrf2 pathway, a major cellular defense against oxidative stress. Conversely, chelation therapy aimed at removing pro-oxidant metals like excess iron or copper, or toxic heavy metals (Pb, Cd, As), can reduce the catalytic generation of ROS via Fenton-like reactions and limit direct oxidative damage. Restoring redox homeostasis is crucial, as oxidative stress drives many pathological processes in CVD, including endothelial dysfunction, inflammation, lipid peroxidation, and DNA damage.
*   **Inflammation:** Metal ion status is closely intertwined with inflammation. Supplementation with magnesium and zinc has been shown in clinical trials to reduce levels of systemic inflammatory markers like hs-CRP, IL-6, and TNF-α. Since oxidative stress often triggers or amplifies inflammatory responses, interventions that improve redox balance through metal ion modulation can indirectly exert anti-inflammatory effects. Conversely, heavy metal exposure can directly provoke inflammation. Modulating inflammation is key, as it plays a central role in atherosclerosis progression, plaque instability, and adverse cardiac remodeling.
*   **Endothelial Function:** The health of the vascular endothelium is paramount for cardiovascular homeostasis. Metal ion modulation can influence endothelial function through several mechanisms. By reducing oxidative stress and inflammation, interventions can help restore the bioavailability of nitric oxide (NO), a critical vasodilator and anti-atherogenic molecule produced by endothelial cells. Some ions may have more direct effects; for example, copper has been suggested to catalyze endogenous NO production under certain conditions. Conversely, heavy metals and dysregulated copper levels can directly impair endothelial cell function and contribute to vascular damage.

### **5.2. Influence on Cardiac Electrophysiology, Blood Pressure, and Angiogenesis**

Metal ions also exert direct effects on specific cardiovascular functions:

*   **Cardiac Electrophysiology:** Magnesium's established antiarrhythmic properties are largely attributed to its modulation of cardiac ion channels, particularly its inhibitory effect on L-type calcium channels and its influence on various potassium channels involved in repolarization. This helps stabilize the membrane potential and prevent aberrant electrical activity. Zinc also modulates cardiac and vascular ion channels. Dysregulation of copper homeostasis has been linked to arrhythmias.
*   **Blood Pressure Regulation:** Vascular tone is influenced by several metal ions. Magnesium promotes vasodilation, potentially by acting as a calcium antagonist in smooth muscle cells. Zinc may also induce vasorelaxation by inhibiting voltage-gated calcium channels in vascular smooth muscle. Conversely, exposure to heavy metals like lead, cadmium, and arsenic is associated with the development of hypertension.
*   **Angiogenesis:** The formation of new blood vessels (angiogenesis) is crucial for tissue repair following ischemic injury, such as myocardial infarction. Several metal ions, including copper, magnesium, cobalt, strontium, and potentially silver, have been shown to promote angiogenesis. These effects are often mediated through the upregulation of hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF), key regulators of the angiogenic process. For instance, copper is recognized as an effective angiogenesis stimulator, affecting endothelial cell proliferation and migration, while cobalt can mimic hypoxia to induce HIF-1α and VEGF expression. Magnesium promotes angiogenesis by increasing secretion of VEGF, eNOS, and PDGF-BB. This pro-angiogenic potential makes these ions attractive candidates for therapeutic strategies aimed at improving tissue perfusion in ischemic CVDs.

### **5.3. Role in Cardiac Remodeling, Fibrosis, and Metal-Induced Cell Death**

Metal ions also play significant roles in the structural integrity of the heart and in determining cell fate under stress conditions.

*   **Cardiac Remodeling and Fibrosis:** Adverse cardiac remodeling, characterized by hypertrophy and excessive fibrosis, is a common pathway leading to heart failure. Imbalances in the metabolism of iron (both deficiency and overload), copper, calcium, and zinc are implicated in this process. These ions influence remodeling through effects on redox signaling, mitochondrial function, fibroblast activation, collagen synthesis, and the activity of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) involved in extracellular matrix turnover. Correcting specific deficiencies (e.g., providing copper or iron where needed) or managing overload (e.g., iron chelation) may therefore have therapeutic potential in mitigating adverse remodeling and fibrosis.
*   **Metal-Induced Cell Death Pathways:** Recent research has highlighted specific forms of regulated cell death driven by metal ions that contribute to cardiovascular pathology. Ferroptosis, an iron-dependent process involving lethal lipid peroxidation, is implicated in iron-overload cardiomyopathy, atherosclerosis, and ischemia-reperfusion injury. Cuproptosis, a distinct pathway triggered by excess copper leading to the aggregation of mitochondrial lipoylated proteins, is also emerging as relevant in CVD. Other forms of cell death like apoptosis and necroptosis can also be influenced by various metal ions. Understanding these specific pathways opens avenues for targeted therapies; for example, inhibiting ferroptosis or cuproptosis through specific pharmacological agents or by managing the underlying metal imbalance (e.g., using iron chelators) could potentially protect the heart from injury.

The pleiotropic nature of most essential metal ions, whereby a single ion influences multiple pathways simultaneously (e.g., magnesium impacting oxidative stress, inflammation, ion channels, and mitochondrial function), complicates efforts to pinpoint a single mechanism of action for observed clinical effects. However, this multi-target engagement might also underlie broader potential benefits. Furthermore, the deepening understanding of specific molecular mechanisms, such as the Nrf2 pathway activation by manganese or the distinct processes of ferroptosis and cuproptosis, provides a foundation for developing novel therapeutic strategies that go beyond simple supplementation or non-specific chelation, perhaps targeting these pathways more directly.

A crucial aspect influencing the translation of these mechanistic potentials into effective therapies is the method of delivery. Simple oral supplementation can be limited by poor bioavailability or systemic side effects, while systemic IV administration may lack target specificity. Consequently, significant research effort is now directed towards developing engineered delivery systems—such as nanoparticles, hydrogels, and functionalized scaffolds—designed to provide controlled, sustained, and potentially targeted release of therapeutic metal ions directly to the site of cardiovascular injury (e.g., ischemic myocardium). These advanced delivery strategies hold promise for enhancing the efficacy and safety of metal ion modulation, particularly for applications like promoting angiogenesis or facilitating tissue repair.

## **6\. Safety, Tolerability, and Future Directions**

While modulating metal ion concentrations holds therapeutic promise, careful consideration of safety, potential adverse effects, diagnostic challenges, and delivery methods is paramount before clinical application.

### **6.1. Adverse Effects, Toxicity, and Contraindications**

The principle that "the dose makes the poison" is particularly relevant for metal ions, including essential ones.

*   **Supplementation Risks:** Many essential minerals exhibit U-shaped or J-shaped dose-response curves, meaning that intakes significantly above physiological requirements can lead to toxicity.
    *   *Magnesium:* Oral magnesium supplements are generally safe but commonly cause dose-dependent gastrointestinal side effects, primarily diarrhea. Intravenous magnesium must be used cautiously in patients with significant renal impairment due to the risk of accumulation and hypermagnesemia.
    *   *Zinc:* High doses of zinc can interfere with the absorption of other essential minerals, notably copper, potentially leading to copper deficiency. Gastrointestinal upset can also occur.
    *   *Selenium:* Selenium has a relatively narrow therapeutic window. Chronic intake of excessive amounts can lead to selenosis, and as discussed previously, supplementation in replete individuals may increase the risk of T2D, alopecia, and dermatitis.
    *   *Iron:* Oral iron preparations are notorious for causing gastrointestinal side effects (constipation, nausea, abdominal pain, dark stools), which often limit adherence. Intravenous iron bypasses these issues but carries risks of acute infusion reactions (though rare with modern formulations), hypophosphatemia, and theoretical concerns about increased susceptibility to infection and potential long-term effects related to bypassing normal iron regulation by hepcidin and generating oxidative stress.
    *   *Copper:* Copper excess is overtly toxic, causing significant oxidative damage and potentially harming multiple organs, including the heart.
*   **Chelation Risks:** Chelation therapy also carries potential risks.
    *   *EDTA:* While generally considered low risk when administered properly according to established protocols (slow infusion rate, adequate hydration, monitoring of renal function), rapid infusion or use in patients with pre-existing kidney disease can lead to nephrotoxicity. Hypocalcemia is a potential complication. A major concern remains the indirect harm if patients use EDTA chelation as a substitute for evidence-based cardiovascular therapies.
    *   *Iron Chelators:* Agents used for iron overload (deferoxamine, deferiprone, deferasirox) have distinct side effect profiles that can include gastrointestinal disturbances, renal toxicity, hepatic dysfunction, and less commonly, auditory or ocular toxicity, requiring careful monitoring.
*   **Heavy Metal Toxicity:** Non-essential heavy metals like lead, cadmium, arsenic, and mercury are inherently toxic even at low exposure levels, causing systemic damage that includes the cardiovascular system.
*   **Contraindications:** Significant renal failure is a major contraindication or requires extreme caution for interventions involving IV magnesium or EDTA due to impaired excretion. It is crucial to confirm the presence of a deficiency state before initiating supplementation (e.g., avoid iron supplements in iron overload) and vice versa for chelation.

The potential for adverse effects necessitates a careful risk-benefit assessment for any proposed metal ion modulation strategy. For interventions where efficacy is marginal, unproven, or limited to specific subgroups (like EDTA for atherosclerosis or selenium for primary prevention in replete populations), even relatively minor safety concerns or theoretical risks become significant barriers to widespread recommendation. Conversely, for interventions with clearly demonstrated benefits for important clinical outcomes (like IV iron reducing HF hospitalizations), the benefits may be judged to outweigh the known or potential risks in appropriately selected patients, leading to guideline endorsements.

### **6.2. Challenges in Diagnostics, Monitoring, and Delivery**

Effective and safe application of metal ion therapies faces several practical challenges:

*   **Diagnostics:** Accurately assessing the true functional status of certain metal ions within the body remains a significant hurdle. Simple plasma or serum measurements may not adequately reflect intracellular concentrations or total body stores, particularly for ions like magnesium, copper, and especially iron in the context of inflammatory states like heart failure. Ferritin, for example, is unreliable as a sole marker of iron status in HF due to its nature as an acute phase reactant. This diagnostic uncertainty is a major barrier, as interventions cannot be reliably targeted to individuals who stand to benefit most (i.e., those with true, functionally relevant deficiency or overload). Without accurate diagnostics, clinical trial results may be diluted by including participants who do not have the condition being targeted, and clinical application becomes imprecise, potentially exposing patients to unnecessary treatment or risks. The development and validation of more reliable biomarkers of functional metal ion status are crucial.
*   **Monitoring:** For interventions involving ions with narrow therapeutic ranges (like selenium) or those carrying potential toxicity with accumulation (like IV iron or chelation agents), appropriate monitoring of ion levels, relevant biomarkers (e.g., ferritin, TSAT for iron therapy), and potential side effects (e.g., renal function, phosphate levels with IV iron) is essential.
*   **Delivery:** Optimizing the delivery of metal ions is key to enhancing efficacy while minimizing toxicity. Oral supplementation often suffers from poor bioavailability (e.g., oral iron in HF) or gastrointestinal intolerance. Intravenous administration overcomes absorption barriers but can lead to rapid fluctuations in plasma levels and lacks tissue specificity. Research into novel oral formulations with improved absorption and tolerability (e.g., sucrosomial iron) and advanced delivery systems like nanoparticles, hydrogels, or biocompatible scaffolds designed for controlled, sustained, or targeted release is a critical area for improving the therapeutic potential of metal ions.

### **6.3. Knowledge Gaps and Priorities for Future Research**

Despite considerable research, significant knowledge gaps remain, highlighting priorities for future investigation:

*   **High-Quality RCTs:** There is a persistent need for more large-scale, long-term, rigorously designed RCTs to definitively establish the efficacy and safety of many potential interventions, including magnesium for primary CVD prevention, zinc supplementation for reducing hard clinical outcomes (beyond risk factors), selenium supplementation in documented deficient populations, and clarification of EDTA's role via TACT2.
*   **Optimal Regimens:** Research is needed to define the optimal dosing, duration, formulation, and target populations for supplementation strategies, considering factors like baseline status and potential U-shaped response curves.
*   **Improved Diagnostics:** Developing and validating better, more accessible biomarkers that accurately reflect functional tissue status for ions like iron, magnesium, and copper, especially in inflammatory conditions, is a high priority.
*   **Comparative Effectiveness:** Head-to-head trials comparing different formulations or delivery routes (e.g., newer oral iron formulations vs. IV iron in HF) are needed.
*   **Long-Term Safety:** More data on the long-term safety of chronic interventions like IV iron therapy or chelation are required.
*   **Mechanistic Insights:** Continued investigation into the fundamental mechanisms by which metal ions influence cardiovascular pathophysiology (e.g., specific roles in ferroptosis, cuproptosis, inflammation, remodeling) can identify novel therapeutic targets.
*   **Interactions:** Better understanding of the complex interactions between different essential minerals and nutrients is needed, as interventions targeting one may affect others.
*   **Delivery Systems:** Further development and clinical testing of advanced delivery systems (nanotechnology, biomaterials) to optimize metal ion therapy are warranted.
*   **Diverse Populations:** Research needs to include more diverse populations beyond those predominantly studied in past trials (e.g., broaden beyond US males for selenium trials).

The significant ongoing research activity focusing on mechanisms and novel delivery strategies suggests continued scientific interest and the potential for future breakthroughs in harnessing metal ion modulation for cardiovascular health. However, the current translation of this research into widely accepted, evidence-based clinical practice remains limited to a few specific, well-defined areas (primarily IV iron in HF-ID, magnesium for specific arrhythmias, chelation for specific overloads). This gap between preclinical promise or mechanistic understanding and proven clinical application highlights the substantial hurdles—including diagnostic uncertainty, safety concerns, and the need for large, expensive clinical trials—that must be overcome for broader implementation of metal ion modulation strategies.

## **7\. Conclusion and Recommendations**

### **7.1. Synthesis of Evidence: Feasibility, Efficacy, and Potential Role**

Modulating plasma and tissue concentrations of metal ions represents a biologically plausible approach to influencing cardiovascular health, given the fundamental roles these elements play in cardiac and vascular physiology and the established links between their dyshomeostasis and CVD pathogenesis. However, the clinical evidence supporting the feasibility, efficacy, and safety of specific interventions varies dramatically.

*   **Feasibility:** Supplementation with oral minerals is generally feasible, although limited by bioavailability and tolerability for some ions (e.g., oral iron). IV administration overcomes absorption issues but requires healthcare infrastructure. Chelation therapy is established for specific overload conditions but remains controversial and less practical for broad applications like atherosclerosis prevention. Advanced delivery systems are promising but largely experimental currently.
*   **Efficacy:** The evidence for clinical efficacy ranges from strong to weak or negative:
    *   **Strongest Evidence:** Intravenous iron (FCM, ferric derisomaltose) demonstrates consistent efficacy in reducing heart failure hospitalizations and improving symptoms and quality of life in patients with HFrEF or HFmrEF and documented iron deficiency. Magnesium sulfate is effective for specific arrhythmias (Torsades de Pointes) and prophylaxis against post-operative atrial fibrillation. Iron and copper chelation are life-saving interventions in specific metal overload diseases like thalassemia and Wilson's disease.
    *   **Moderate Evidence:** Supplementation with magnesium and zinc shows consistent benefits in improving cardiometabolic risk factors (glycemic control, lipid profiles, inflammation markers) in meta-analyses of RCTs. Observational data link higher Mg and Zn status to lower risks of certain CVD outcomes (stroke, HF, T2D for Mg; CVD in T2D for Zn).
    *   **Weak/Inconclusive/Negative Evidence:** Selenium supplementation for primary CVD prevention in generally well-nourished populations lacks supporting evidence from high-quality RCTs and may increase T2D risk. EDTA chelation therapy for atherosclerosis remains controversial, with insufficient evidence for routine use despite the TACT trial. Oral iron therapy is ineffective for ID in HF. Evidence regarding copper modulation for general CVD prevention is conflicting and insufficient. IV iron therapy has not conclusively demonstrated a mortality benefit in HF.

### **7.2. Recommendations Based on Strength of Evidence**

Based on the critical evaluation of the current evidence:

*   **Recommended:**
    *   Screening for and treatment of iron deficiency with intravenous iron (specifically formulations like FCM or ferric derisomaltose with trial evidence) should be implemented for symptomatic HFrEF and HFmrEF patients meeting guideline criteria for ID, aiming to reduce HF hospitalizations and improve symptoms/QoL.
    *   Intravenous magnesium sulfate should be used for the treatment of Torsades de Pointes and considered for prophylaxis against post-operative atrial fibrillation and as adjunctive therapy for ventricular rate control in acute AF.
    *   Appropriate iron or copper chelation therapy should be utilized for patients with diagnosed iron overload (e.g., thalassemia) or copper overload (Wilson's disease), respectively, under specialist care.
*   **Consider:**
    *   Magnesium or zinc supplementation may be considered as adjunctive therapy to target cardiometabolic risk factors (e.g., improving glycemic control or lipid profiles) in individuals with documented or high risk of deficiency, or in specific high-risk groups like those with T2D, acknowledging the current lack of definitive RCT evidence for reduction in hard clinical endpoints.
*   **Not Recommended (Based on Current Evidence for General CVD Prevention/Treatment):**
    *   Routine selenium supplementation for primary prevention of CVD in individuals residing in areas with adequate selenium intake is not recommended due to lack of benefit and potential harm (increased T2D risk).
    *   Routine use of EDTA chelation therapy for the treatment or prevention of atherosclerotic cardiovascular disease is not supported by current evidence.
    *   Oral iron supplementation should not be used as the primary treatment for iron deficiency in patients with heart failure due to lack of efficacy.

### **7.3. Concluding Remarks on Balancing Benefits and Risks**

The modulation of metal ion concentrations offers a potential therapeutic avenue for certain cardiovascular conditions, but its application requires a nuanced and evidence-based approach. The significant variability in efficacy across different ions, interventions, and patient populations, coupled with the challenges in accurately diagnosing deficiencies or excesses and the potential for toxicity associated with inappropriate use, underscores the need for caution. A 'one-size-fits-all' strategy is clearly inappropriate. Future success in this field likely depends on adopting a precision medicine approach: identifying the right patient (with confirmed, relevant dyshomeostasis using reliable diagnostics), selecting the right intervention (specific ion, dose, formulation, route), for the right indication, and carefully monitoring for both benefit and harm. The complex interplay between different metal ions also suggests that focusing solely on single-ion interventions might be insufficient, potentially necessitating strategies aimed at restoring overall mineral balance or targeting common downstream pathological pathways like oxidative stress and inflammation. While research continues to uncover intricate mechanistic roles and develop novel delivery technologies, translating these advances into safe and effective clinical practice requires ongoing rigorous evaluation through high-quality clinical trials. Balancing the potential, often modest or specific benefits against the real risks of toxicity, side effects, cost, and the potential diversion from established, proven therapies remains the central challenge in integrating metal ion modulation into the broader landscape of cardiovascular therapeutics."
</article_1>

<article_2>
"# Modulating Plasma Metal Ions to Prevent or Treat Cardiovascular Disease: An Evidence-Based Analysis

## TL;DR

- **Metal-ion modulation is a real but narrow therapeutic strategy in cardiovascular medicine: the one intervention with guideline-endorsed, outcome-changing evidence is intravenous iron repletion in iron-deficient heart failure. Correcting a genuine deficiency or overload (iron, copper, selenium in deficient populations) works; broadly supplementing metals in replete people or chelating "toxic" metals in unselected patients does not.**
- **EDTA chelation, once promising after TACT (2013), was refuted by the larger, better-controlled TACT2 (2024), which showed no cardiovascular benefit despite effectively lowering blood lead and cadmium. Toxic metals (lead, cadmium, arsenic) are now recognized causal CVD risk factors, but the answer is exposure prevention, not chelation.**
- **Most oral supplementation (selenium, zinc, magnesium, calcium) shows benefit only in deficiency states or on surrogate markers (blood pressure, arrhythmia), not hard outcomes in replete populations; calcium supplements may modestly increase MI risk. Copper chelation for cardiac hypertrophy (trientine) is the most promising emerging pharmacological approach but remains phase 2.**

## Key Findings

1. **Iron is the standout success.** IV iron (ferric carboxymaltose/derisomaltose) in iron-deficient HFrEF/HFmrEF reduces heart-failure hospitalizations. The 2025 individual-participant meta-analysis by Anker SD et al. (*Nature Medicine* 2025;31(8):2640–2646) of six trials (7,175 patients) found patients assigned to IV iron "had lower rates for the composite endpoint of recurrent HF hospitalizations and cardiovascular mortality at 12 months (risk ratio (RR) = 0.72 (95% confidence interval (CI) = 0.55–0.89))."  This underpins Class I (symptoms/QoL) and Class IIa (hospitalization reduction) recommendations in the 2023 ESC HF guideline update.
2. **EDTA chelation failed replication.** TACT (Lamas GA et al., *JAMA* 2013) suggested an 18% CVD-event reduction in 1,708 post-MI patients with a 41% reduction in the diabetic subgroup; TACT2 (Lamas GA et al., *JAMA* 2024;332(10):794–803), which randomized 1,000 diabetic post-MI patients across 88 US/Canadian sites, found no benefit (35.6% vs 35.7% events) despite a 61% reduction in blood lead.
3. **Toxic metals are causal CVD risk factors** (AHA 2023 scientific statement), but the intervention is prevention of exposure, not chelation treatment.
4. **Selenium/CoQ10** reduced CV mortality in a Swedish trial of selenium-deficient elderly (KiSel-10), but selenium in replete populations (SELECT) showed no CV benefit.
5. **Copper chelation (trientine)** reduces LV mass in diabetic heart disease and, in the newly published phase 2 TEMPEST trial, in hypertrophic cardiomyopathy—an emerging, mechanistically novel approach.

## Details

### 1. Background and mechanisms

Metal ions participate in cardiovascular pathophysiology through several converging mechanisms:

- **Redox chemistry / oxidative stress:** Redox-active metals (iron, copper) catalyze Fenton and Haber-Weiss reactions generating reactive oxygen species (ROS), driving lipid peroxidation, oxidation of LDL, and endothelial injury. Iron-dependent lipid peroxidation defines **ferroptosis**, a regulated cell-death pathway now implicated in atherosclerosis, ischemia-reperfusion injury, myocardial infarction, heart failure, and doxorubicin cardiomyopathy.
- **Enzyme cofactor roles:** Selenium is incorporated into selenoproteins (glutathione peroxidases, thioredoxin reductases) central to antioxidant defense. Copper is a cofactor for cytochrome c oxidase (mitochondrial respiration), superoxide dismutase (SOD1), lysyl oxidase (connective-tissue crosslinking), and ceruloplasmin.  Zinc is a structural/catalytic cofactor for roughly 10% of the human proteome,  including Cu/Zn-SOD, and is chemically inert (acting as an antioxidant partly by displacing redox-active metals).
- **Endothelial dysfunction and inflammation:** Toxic metals (lead, cadmium, arsenic) and metal dyshomeostasis promote endothelial dysfunction, vascular inflammation (VCAM-1, ICAM-1, MCP-1 upregulation), and disturbed lipid metabolism.
- **Myocardial function:** Selenium deficiency causes Keshan disease (dilated cardiomyopathy); copper deficiency causes cardiac hypertrophy and heart failure in models; iron overload causes iron-overload cardiomyopathy; iron deficiency impairs mitochondrial energetics in cardiomyocytes.
- **Vascular calcification:** Calcium-phosphate (hydroxyapatite) deposition in the arterial intima and media drives coronary artery calcification; zinc suppresses phosphate-induced vascular calcification in vitro.
- **Metallothioneins:** Cysteine-rich, low-molecular-weight metal-binding proteins that buffer zinc, scavenge free radicals, and detoxify heavy metals; cardioprotective in overexpression models (e.g., MT-IIA-overexpressing cardiac cell lines confer oxidative protection).

### 2. Types of interventions proposed

**Essential trace element supplementation** — zinc, selenium, magnesium, copper, iron. Rationale is repletion of deficiency; efficacy depends critically on baseline status.

**Chelation therapy** — EDTA (edetate disodium) for lead/cadmium/calcium; DMSA and others for heavy metals; copper-selective chelators (trientine, tetrathiomolybdate); iron chelators (deferoxamine, deferasirox, deferiprone) for overload.

**Dietary interventions** — reducing toxic-metal intake (contaminated water/food), Mediterranean-diet fish intake balancing omega-3 benefit against methylmercury, dietary magnesium and zinc.

**Pharmacological metal-homeostasis modulation** — copper chelation for cardiac remodeling; iron-restriction/ferroptosis inhibitors (investigational); hepcidin pathway modulation.

**Metal-binding proteins / metallothionein modulation** — largely preclinical; metallothionein overexpression is cardioprotective against oxidative stress.

**Novel approaches** — SNF472 (hexasodium phytate, an intravenous hydroxyapatite-crystallization inhibitor) for vascular calcification; nanoparticle and ionophore approaches remain experimental.

### 3. Iron and cardiovascular disease

**Iron deficiency in heart failure (the strongest evidence base):**

- **AFFIRM-AHF** (acute HF, ferric carboxymaltose) and **IRONMAN** (chronic HF, ferric derisomaltose) both narrowly missed their primary composite endpoints but showed benefit in pre-specified COVID-adjusted analyses.
- **HEART-FID** (3,065 patients, ferric carboxymaltose; *NEJM* 2023) did not reach significance at the pre-specified 99% CI but was significant at the conventional 95% CI.
- **2025 Nature Medicine meta-analysis** (Anker SD et al., *Nat Med* 2025;31(8):2640–2646; FAIR-HF, CONFIRM-HF, AFFIRM-AHF, IRONMAN, HEART-FID, FAIR-HF2; 7,175 patients; Bayesian, individual-participant data): RR 0.72 (95% CI 0.55–0.89) for recurrent HF hospitalizations plus CV death at 12 months; RR 0.81 (0.63–0.97) over full follow-up.
- **ESC 2023 focused update:** IV iron Class I (Level A) to improve symptoms/QoL; Class IIa (Level A) to reduce HF hospitalization in symptomatic HFrEF/HFmrEF with iron deficiency  (defined as ferritin <100 ng/mL, or 100–299 with TSAT <20%).

**Iron overload:** Hereditary hemochromatosis and transfusion-dependent β-thalassemia cause iron-overload cardiomyopathy (diastolic dysfunction and arrhythmias progressing to systolic failure); in inherited hemochromatosis, cardiac iron damage is a leading cause of death. Management is phlebotomy or iron chelation (deferoxamine, deferasirox, deferiprone) with cardiac MRI T2* monitoring. Ferroptosis and macrophage iron overload contribute to atherosclerosis progression in models.

### 4. Selenium

- **Keshan disease:** endemic selenium-deficiency dilated cardiomyopathy in low-selenium regions of China (first described 1935); selenium salt supplementation dramatically reduced incidence. In chronic Keshan disease with congestive heart failure, a 10-year follow-up found selenium supplementation associated with reduced cardiac death (HR 0.39, 95% CI 0.28–0.53).
- **KiSel-10 (Alehagen et al.):** Swedish RCT, 443 elderly with low selenium, 200 µg/day selenized yeast + 200 mg/day CoQ10 for 48 months. Reduced CV mortality persisting long after the intervention ended: HR 0.51 (95% CI 0.36–0.74; P=0.0003) at 10 years (*PLoS One* 2015;10(12):e0141641), and at 12 years CV mortality was 28.1% (active) vs 38.7% (placebo), HR 0.59 (95% CI 0.42–0.81; P=0.001) (*PLoS One* 2018;13(4):e0193120).
- **SELECT:** 35,533 men, 200 µg L-selenomethionine ± vitamin E; no reduction in prostate cancer and no CV benefit (the population was selenium-replete). Vitamin E was associated with a 17% increased prostate cancer risk.
- **Interpretation:** Benefit appears confined to selenium-deficient populations. High selenium has been associated with increased hypertension and type 2 diabetes risk—consistent with a U-shaped exposure-risk relationship.

### 5. Zinc

Zinc deficiency is associated with atherosclerosis, myocardial infarction, and ischemia-reperfusion injury in mechanistic studies, acting via anti-oxidant and anti-inflammatory pathways and metallothionein induction. A GRADE-assessed dose-response meta-analysis found zinc supplementation improved lipid and glycemic risk factors for type 2 diabetes and CVD; doses studied ranged from ~9.8 to 75 mg/day elemental zinc. In patients with type 2 diabetes and coronary heart disease, magnesium (250 mg) plus zinc (150 mg zinc sulfate) co-supplementation for 12 weeks improved fasting glucose, insulin, HDL, and CRP. In hemodialysis populations, low zinc predicts mortality and supplementation improves oxidative-stress markers. Evidence is on surrogate markers, not hard CVD outcomes.

### 6. Magnesium

- **Blood pressure:** 2025 meta-analysis (38 RCTs, 2,709 participants, median 365 mg/day elemental magnesium): SBP −2.81 mmHg (95% CI −4.32 to −1.29), DBP −2.05 mmHg (−3.23 to −0.88) overall; larger reductions in hypertensives on antihypertensive medication (SBP −7.68) and in hypomagnesemic patients (SBP −5.97). No significant effect in normotensives.
- **Arrhythmia:** meta-analysis (22 studies) of magnesium after acute coronary syndrome reduced ventricular arrhythmia (OR 0.32, 95% CI 0.16–0.49) and supraventricular arrhythmia (OR 0.42, 95% CI 0.22–0.65). IV magnesium is established therapy for torsades de pointes and for post-cardiac-surgery atrial fibrillation prophylaxis.

### 7. Copper

- **Deficiency:** causes cardiac hypertrophy, heart failure, and cardiomyopathy in animal models (reduced cytochrome c oxidase, SOD, and lysyl oxidase activity); copper repletion reverses these.
- **Excess/dysregulation:** elevated serum copper/ceruloplasmin correlates with CVD risk and heart-failure severity; cuproptosis (copper-dependent cell death) is an emerging mechanism.
- **Copper chelation (trientine) — the most promising emerging pharmacological approach:**

  
  - **Cooper GJS et al. (*Diabetologia* 2009;52(4):715–722):** 12-month randomized, double-blind, placebo-controlled trial in 30 type-2-diabetic patients with LV hypertrophy; trientine 1,200 mg/day. LV mass index by cardiac MRI fell −10.6 ± 7.6 g/m² (trientine) vs −0.1 ± 9.8 g/m² (placebo) at 12 months (P=0.0088), without changes in blood pressure or glycemia.  Notably small (n=15/group, only 9 trientine patients analyzed at 12 months) and industry-linked (Protemix).
  - **TEMPEST (phase 2, hypertrophic cardiomyopathy; Farrant JP et al.):** multicentre, double-blind, placebo-controlled trial; 154 randomized (79 trientine, 75 placebo), 800 mg/day trientine base for 52 weeks.  Primary endpoint change in LV mass index by CMR: −4.4 g/m² (trientine) vs −1.5 g/m² (placebo), between-group difference −3.2 g/m² (95% CI −5.6 to −0.8; P=0.009), with greater effect at higher baseline LV mass and mediation via reduced myocardial cellular mass.  Well tolerated (more anemia and hypocupraemia with trientine).  The design was published in *Heart* 2023;109:1175–1182 (NCT04706429); the trial is the first non-sarcomere-targeted therapy to reduce LV mass in HCM,  but phase 3 trials with clinical endpoints are required.
- **Tetrathiomolybdate:** copper chelation reduced atherosclerotic lesion development by ~25% (whole aorta) to ~45% (descending aorta) in ApoE-deficient mice  (Wei H et al., *Atherosclerosis* 2012;223:306–313), with reduced vascular inflammation; no human cardiovascular outcome trials exist (human use has been in Wilson's disease and oncology).

### 8. Toxic heavy metals (lead, cadmium, arsenic, mercury)

- **AHA 2023 scientific statement** (*J Am Heart Assoc*): chronic low/moderate exposure to lead, cadmium, and arsenic increases the risk of coronary artery disease, stroke, and peripheral artery disease; environmental cardiology now treats these as modifiable risk factors.
- **Lead:** Lanphear BP et al. (*Lancet Public Health* 2018; NHANES-III cohort of 14,289 adults) estimated ~256,000 premature CVD deaths per year in the US attributable to lead (including ~185,000 from ischaemic heart disease),  of ~412,000 total lead-attributable deaths (18% of all mortality);  CVD-mortality HR 1.70 (95% CI 1.30–2.22) comparing the 90th vs 10th percentile of blood lead.  Pooled RRs (high vs low blood lead) elsewhere: 1.43 for CVD, 1.85 for CHD, 1.63 for stroke.
- **Cadmium:** 2023 meta-analysis (21 studies): RR 1.36 (95% CI 1.22–1.50) for CVD, 1.73 for heart disease, 1.28 for stroke; separate dose-response meta-analyses confirm positive associations with hypertension. (Smoking is a major cadmium source—an important confounder.)
- **Arsenic:** Strong Heart Study—each interquartile increase in urinary arsenic (12.5 µg/L) associated with all-cause mortality HR 1.28 and CV mortality HR 1.28; low-to-moderate exposure linked to incident CVD, with mechanisms including oxidative stress, inflammation, and endothelial dysfunction.
- **Mercury:** methylmercury from fish is neurotoxic and may increase CV risk by inhibiting selenoenzymes, but selenium co-ingestion and omega-3 benefits complicate the picture; the PREDIMED nested case-control study found no increased CVD risk from mercury exposure in high-fish-consuming Spanish adults (fully-adjusted RR 0.71 for highest vs lowest quartile).
- **Intervention:** The consensus is exposure reduction (regulation, water/soil/air monitoring, abatement); chelation is not recommended for cardiovascular prevention (see TACT2 below).

### 9. EDTA chelation therapy

- **TACT (Lamas GA et al., *JAMA* 2013;309(12):1241–1250):** 1,708 post-MI patients; 40 EDTA infusions; a significant 18% reduction in the composite endpoint (cardiac event in 26% chelation vs 30% placebo); a large benefit in the pre-specified diabetic subgroup (HR 0.59, 95% CI 0.44–0.79) with a 41% relative reduction. The authors cautioned these results were not sufficient to support routine use.
- **TACT2 (Lamas GA et al., *JAMA* 2024;332(10):794–803):** 1,000 diabetic post-MI patients across 88 US/Canadian sites (959 received ≥1 infusion);  **no benefit**—CV events 35.6% (chelation) vs 35.7% (placebo); CV death/MI/stroke  18.4% vs 19.7%; all-cause death 17.4% vs 17.6%—despite a statistically significant 61% reduction in blood lead  (median 9.03→2.46 µg/L) and increased urinary cadmium excretion.
- **Verdict:** The toxic-metal-chelation hypothesis for secondary prevention is not supported by the definitive replication trial. EDTA chelation should not be used to reduce cardiovascular events.

### 10. Calcium

- **Vascular calcification:** the coronary artery calcium score (Agatston) is a strong, specific marker of atherosclerotic burden and predicts CV events; notably, statins reduce events but do not reliably reduce established calcium scores.
- **Calcium supplements and risk:** Bolland et al. meta-analyses found calcium supplements without vitamin D increased MI risk ~27–31% (e.g., HR 1.31, 95% CI 1.02–1.67 in individual-patient analysis of 8,151 subjects); a 2016 *Annals of Internal Medicine* meta-analysis found calcium ± vitamin D increased MI (pooled RR 1.24, 95% CI 1.07–1.45) and stroke (RR 1.15). Other meta-analyses (e.g., 2021, 12 RCTs) found no significant association—evidence is genuinely conflicting, but the signal favors caution with high-dose supplements versus dietary calcium (dietary calcium does not appear to raise risk).
- **SNF472 (hexasodium phytate):** In the CaLIPSO phase 2 trial (Raggi P et al., *Circulation* 2020;141(9):728–739), 274 hemodialysis patients were randomized 1:1:1 to SNF472 300 mg, 600 mg, or placebo  infused thrice weekly during dialysis over 52 weeks; the mean change in coronary artery calcium volume score was "11% (95% CI, 7–15) for the combined SNF472 dose group and 20% (95% CI, 14–26) for the placebo group (P=0.016)."  SNF472 (also designated CSL525) inhibits hydroxyapatite crystallization and is being developed for calciphylaxis and cardiovascular calcification; endpoints to date are surrogate imaging, not clinical outcomes.

### 11. Feasibility and safety

- **IV iron:** generally well tolerated; hypophosphatemia (notably with ferric carboxymaltose) and rare hypersensitivity reactions.
- **Selenium:** narrow therapeutic window; excess causes selenosis and is linked to increased hypertension and diabetes risk—supplementation should be reserved for deficiency.
- **Copper chelation (trientine):** anemia and hypocupraemia require monitoring (both seen in TEMPEST); GI side effects.
- **EDTA:** hypocalcemia, potential renal risk, and heavy treatment burden (40 infusions)—with no proven cardiovascular benefit.
- **Calcium supplements:** a possible MI signal argues for favoring dietary sources.
- **Patient selection is decisive:** benefit accrues to those with documented deficiency (iron, selenium) or overload (iron), not to replete populations.

## Recommendations

**Stage 1 — Do now (evidence-based clinical practice):**

- Screen all heart-failure patients (HFrEF/HFmrEF) for iron deficiency (ferritin, TSAT) and treat with IV ferric carboxymaltose or ferric derisomaltose per ESC 2023 (Class I to improve symptoms/QoL; Class IIa to reduce HF hospitalization).
- Correct hypomagnesemia; use IV magnesium for torsades de pointes and post-operative AF prophylaxis; consider magnesium in hypertensive patients with low magnesium status.
- Screen for and treat iron overload (hemochromatosis, thalassemia) with phlebotomy/chelation and cardiac MRI T2* monitoring.
- Counsel patients to reduce toxic-metal exposure (water testing, avoiding contaminated food/water/consumer sources); support public-health abatement.
- **Do NOT** use EDTA chelation for cardiovascular event prevention. Advise caution with high-dose calcium supplements; favor dietary calcium.

**Stage 2 — Consider selectively / individualize:**

- Selenium supplementation only in documented deficiency or low-selenium regions; avoid in replete individuals given the U-shaped risk curve.
- Zinc repletion in documented deficiency (e.g., CKD/hemodialysis), where surrogate benefits exist.

**Stage 3 — Investigational (enroll in trials where available):**

- Copper chelation (trientine) for diabetic cardiomyopathy and hypertrophic cardiomyopathy (phase 3 with clinical endpoints needed).
- SNF472 for vascular calcification in dialysis patients (outcome data needed).
- Ferroptosis inhibitors and metallothionein modulation (preclinical).

**Thresholds that would change recommendations:** A positive phase 3 trientine trial with hard endpoints; positive clinical-outcome data for SNF472; or any adequately powered RCT showing chelation reduces events in a well-defined metal-burdened subgroup would reopen the toxic-metal-chelation question.

## Caveats

- Much of the supplementation evidence rests on **surrogate markers** (blood pressure, lipids, arrhythmia counts, imaging) rather than mortality, MI, or stroke.
- **Baseline status confounds everything:** the same intervention can help the deficient and harm the replete (U-shaped curves for selenium, copper, iron, and calcium). Effect sizes generalize poorly across populations with different baseline metal status.
- Several key HF iron trials (AFFIRM-AHF, IRONMAN, HEART-FID) **missed their primary endpoints** on conventional pre-specification and rely on pre-specified COVID-adjusted or meta-analytic significance; the strong meta-analytic signal is nonetheless consistent.
- Observational metal–CVD associations are vulnerable to **residual confounding** (smoking is a major cadmium source; socioeconomic factors track lead exposure).
- The most cited copper-chelation trial (Cooper 2009) was very small (n=30) and industry-linked; the larger, independent TEMPEST trial found a more modest but statistically significant effect on an imaging surrogate, not clinical outcomes.
- SNF472 and copper-chelation efficacy data remain on **surrogate endpoints**, and their translation to reduced events is unproven.
"
</article_2>

**Evaluation Criteria**
Now, you need to evaluate and compare these two articles based on the following **evaluation criteria list**, providing comparative analysis and scoring each on a scale of 0-10. Each criterion includes an explanation, please understand carefully.

<criteria_list>
{
  "comprehensiveness": [
    {
      "criterion": "Scope of Metal Ions and their Cardiovascular Relevance",
      "explanation": "Assesses if the article identifies a comprehensive range of metal ions pertinent to cardiovascular health (e.g., essential macro/micronutrients like Mg, K, Se, Zn, Cu; and potentially toxic elements like Pb, Cd, As if relevant to interventions) and briefly contextualizes their roles or dysregulation in CVD to establish the basis for interventions."
    },
    {
      "criterion": "Breadth of Proposed Intervention Modalities",
      "explanation": "Evaluates if the article covers a wide spectrum of interventions aimed at modulating plasma metal ions (e.g., supplementation, chelation therapy, specific dietary strategies, lifestyle factors affecting metal ion balance), going beyond a narrow focus on a single type if others are relevant."
    },
    {
      "criterion": "Thoroughness of Clinical Evidence on Efficacy",
      "explanation": "Checks if the article presents a comprehensive review of available clinical evidence (from diverse study designs like RCTs, meta-analyses, epidemiological studies) regarding the *efficacy* of these interventions in preventing or treating specified cardiovascular diseases or modifying relevant cardiovascular risk factors."
    },
    {
      "criterion": "Thoroughness of Clinical Evidence on Feasibility and Safety",
      "explanation": "Assesses if the article comprehensively discusses the *feasibility* of the proposed interventions, including critical aspects such as safety profiles (adverse effects, contraindications), patient adherence, routes of administration, monitoring requirements, and, where available, cost-effectiveness based on clinical studies and real-world data."
    },
    {
      "criterion": "Coverage of Preventive and Therapeutic Contexts",
      "explanation": "Evaluates whether the article adequately distinguishes between and discusses the application of metal ion modulation strategies for both primary/secondary *prevention* of CVD in at-risk populations and as *therapeutic* interventions for patients with established cardiovascular diseases."
    },
    {
      "criterion": "Scope of Cardiovascular Diseases Discussed",
      "explanation": "Assesses if the article considers the implications of metal ion interventions for a relevant range of cardiovascular disease types (e.g., hypertension, coronary artery disease, heart failure, arrhythmias, atherosclerosis) or provides appropriate justification if its focus is narrower."
    }
  ],
  "insight": [
    {
      "criterion": "Depth of Mechanistic Rationale for Ion Modulation in CVDs",
      "explanation": "Assesses if the article critically analyzes the biological pathways by which specific metal ions (deficiency or excess) contribute to CVD pathogenesis, and the scientific basis for how their modulation (e.g., via supplementation, chelation) could lead to preventive or therapeutic effects, moving beyond superficial associations."
    },
    {
      "criterion": "Critical Appraisal of Clinical Evidence for Efficacy",
      "explanation": "Evaluates the rigor with which the article assesses clinical trial data and observational studies for various interventions. This includes judging study design quality, statistical robustness, consistency of findings across studies, magnitude and clinical relevance of effects, and differentiation between evidence for prevention versus therapy."
    },
    {
      "criterion": "Critical Appraisal of Clinical Evidence for Feasibility",
      "explanation": "Assesses the depth of analysis regarding the practical aspects of proposed interventions. This includes evaluation of safety profiles (adverse events, toxicity risks from modulation), patient adherence, bioavailability issues, methods for assessing ion status, and challenges in achieving and maintaining target concentrations."
    },
    {
      "criterion": "Synthesis of Evidence and Nuance in Evaluating Overall Potential",
      "explanation": "Evaluates the article's ability to integrate mechanistic understanding, intervention types, and multifaceted clinical evidence (efficacy, feasibility) into a cohesive, balanced, and well-reasoned judgment on the overall potential of metal ion modulation strategies for CVDs. This includes acknowledging conflicting evidence, uncertainties, and the scope of applicability."
    },
    {
      "criterion": "Consideration of Complexities and Confounding Factors",
      "explanation": "Assesses if the article thoughtfully discusses complexities inherent in metal ion modulation, such as homeostatic regulation, ion-ion interactions, impact of baseline nutritional status, genetic predispositions affecting ion metabolism or CVD risk, and potential confounding by other lifestyle or medical factors when interpreting evidence."
    },
    {
      "criterion": "Identification of Knowledge Gaps and Insightful Future Research Directions",
      "explanation": "Evaluates whether the article identifies significant limitations or gaps in current understanding/evidence and proposes specific, well-justified, and potentially impactful avenues for future research (e.g., specific populations, intervention strategies, biomarkers) that could resolve uncertainties or advance the field."
    }
  ],
  "instruction_following": [
    {
      "criterion": "Responsiveness to the Question of Overall Effectiveness for CVDs (Preventive/Therapeutic)",
      "explanation": "Assesses if the article directly addresses the main question of whether modulating plasma metal ion concentrations can be effective preventive or therapeutic strategies specifically against cardiovascular diseases."
    },
    {
      "criterion": "Identification and Description of Proposed Intervention Types",
      "explanation": "Evaluates if the article identifies and describes various types of interventions aimed at modulating plasma metal ion concentrations, as requested by the task."
    },
    {
      "criterion": "Coverage of Clinical Evidence for Intervention Efficacy",
      "explanation": "Assesses if the article presents and discusses clinical evidence regarding the *efficacy* of the identified interventions for CVDs, fulfilling a key part of the evidence requirement."
    },
    {
      "criterion": "Coverage of Clinical Evidence for Intervention Feasibility",
      "explanation": "Assesses if the article presents and discusses clinical evidence regarding the *feasibility* of implementing the identified interventions, fulfilling another key part of the evidence requirement."
    },
    {
      "criterion": "Explicit Addressal of 'Supplementation' as an Intervention Type",
      "explanation": "Checks if the article specifically addresses 'supplementation' as one of the types of interventions, as explicitly mentioned in the task."
    },
    {
      "criterion": "Adherence to 'Cardiovascular Diseases' Scope",
      "explanation": "Ensures the entire discussion, including interventions and evidence, remains focused on cardiovascular diseases and does not significantly deviate to other medical conditions."
    },
    {
      "criterion": "Adherence to 'Modulating Plasma Metal Ion Concentrations' Scope",
      "explanation": "Ensures that the interventions discussed are specifically those aimed at modulating plasma metal ion concentrations, rather than other mechanisms or targets, even if related to CVDs."
    }
  ],
  "readability": [
    {
      "criterion": "Overall Logical Structure and Coherent Flow",
      "explanation": "Assesses if the article follows a clear, logical progression (e.g., introduction to metal ions/CVD, proposed interventions, review of clinical evidence, discussion of feasibility/efficacy, conclusion), with well-defined sections and effective headings. This structure is crucial for enabling readers to easily follow the complex scientific narrative pertinent to metal ions, cardiovascular diseases, and therapeutic interventions."
    },
    {
      "criterion": "Precision and Clarity of Scientific Language and Terminology",
      "explanation": "Evaluates the correct, consistent, and unambiguous use of medical, biochemical, and clinical research terminology (e.g., 'plasma metal ion concentrations,' 'therapeutic interventions,' 'cardiovascular diseases,' 'clinical evidence,' 'feasibility,' 'efficacy'). Key specialized terms should be defined or contextualized if not common knowledge for the target scientific audience, ensuring accurate comprehension of scientific details and arguments."
    },
    {
      "criterion": "Sentence-Level Clarity, Grammar, and Conciseness",
      "explanation": "Assesses if sentences are grammatically correct, clearly constructed, and free from unnecessary jargon or excessive complexity. Writing should be concise and fluent, facilitating smooth comprehension of scientific arguments and evidence related to metal ion interventions without causing reader fatigue or ambiguity."
    },
    {
      "criterion": "Paragraph Cohesion and Effective Transitions",
      "explanation": "Evaluates if each paragraph focuses on a distinct idea or aspect of the topic (e.g., a specific metal ion's role, an intervention type, or a piece of evidence regarding CVD) and is well-developed with supporting details. Smooth and logical transitions between sentences and paragraphs are vital for maintaining argument coherence and guiding the reader through the intricate details of the research."
    },
    {
      "criterion": "Clarity in Presenting Interventions and Clinical Evidence",
      "explanation": "Assesses how clearly the types of therapeutic interventions (e.g., supplementation) are described and how clinical evidence regarding their feasibility and efficacy for cardiovascular diseases is summarized, explained, and critically discussed. This includes the lucidity of presenting study methodologies, patient outcomes, and limitations, making complex findings accessible and understandable."
    },
    {
      "criterion": "Effectiveness of Formatting, Layout, and Visual Aids (if any)",
      "explanation": "Evaluates the overall visual presentation, including consistent formatting (e.g., headings, font, spacing, citations if applicable), readability of text, and the clarity, relevance, and integration of any tables or figures used to summarize information (such as types of interventions, key studies, or outcomes). Good design enhances comprehension, reduces reader fatigue, and supports the professional appearance of the research article."
    }
  ]
}
</criteria_list>

<Instruction>
**Your Task**
Please strictly evaluate and compare `<article_1>` and `<article_2>` based on **each criterion** in the `<criteria_list>`. You need to:
1.  **Analyze Each Criterion**: Consider how each article fulfills the requirements of each criterion.
2.  **Comparative Evaluation**: Analyze how the two articles perform on each criterion, referencing the content and criterion explanation.
3.  **Score Separately**: Based on your comparative analysis, score each article on each criterion (0-10 points).

**Scoring Rules**
For each criterion, score both articles on a scale of 0-10 (continuous values). The score should reflect the quality of performance on that criterion:
*   0-2 points: Very poor performance. Almost completely fails to meet the criterion requirements.
*   2-4 points: Poor performance. Minimally meets the criterion requirements with significant deficiencies.
*   4-6 points: Average performance. Basically meets the criterion requirements, neither good nor bad.
*   6-8 points: Good performance. Largely meets the criterion requirements with notable strengths.
*   8-10 points: Excellent/outstanding performance. Fully meets or exceeds the criterion requirements.

**Output Format Requirements**
Please **strictly** follow the `<output_format>` below for each criterion evaluation. **Do not include any other unrelated content, introduction, or summary**. Start with "Standard 1" and proceed sequentially through all criteria:
</Instruction>

<output_format>
{
    "comprehensiveness": [
        {
            "criterion": [Text content of the first comprehensiveness evaluation criterion],
            "analysis": [Comparative analysis],
            "article_1_score": [Continuous score 0-10],
            "article_2_score": [Continuous score 0-10]
},
{
            "criterion": [Text content of the second comprehensiveness evaluation criterion],
            "analysis": [Comparative analysis],
            "article_1_score": [Continuous score 0-10],
            "article_2_score": [Continuous score 0-10]
        },
        ...
    ],
    "insight": [
        {
            "criterion": [Text content of the first insight evaluation criterion],
            "analysis": [Comparative analysis],
            "article_1_score": [Continuous score 0-10],
            "article_2_score": [Continuous score 0-10]
        },
        ...
    ],
    ...
}
</output_format>

Now, please evaluate the two articles based on the research task and criteria, providing detailed comparative analysis and scores according to the requirements above. Ensure your output follows the specified `<output_format>` and that the JSON format is parsable, with all characters that might cause JSON parsing errors properly escaped.
</user_prompt>
